<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Physiol</journal-id><journal-id journal-id-type="iso-abbrev">J. Physiol. (Lond.)</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1469-7793</journal-id><journal-id journal-id-type="publisher-id">TJP</journal-id><journal-id journal-id-type="hwp">jphysiol</journal-id><journal-title-group><journal-title>The Journal of Physiology</journal-title></journal-title-group><issn pub-type="ppub">0022-3751</issn><issn pub-type="epub">1469-7793</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26970080</article-id><article-id pub-id-type="pmc">4983615</article-id><article-id pub-id-type="doi">10.1113/JP271106</article-id><article-id pub-id-type="publisher-id">TJP7198</article-id><article-categories><subj-group subj-group-type="article-subject-classification"><subject>Cellular and Molecular Neuroscience</subject></subj-group><subj-group subj-group-type="article-subject-classification"><subject>Neurological Conditions, Disorders and Treatments</subject></subj-group><subj-group subj-group-type="overline"><subject>Symposium Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Symposium Reviews</subject></subj-group></article-categories><title-group><article-title>Does modulation of the endocannabinoid system have potential therapeutic utility in cerebellar ataxia?</article-title><alt-title alt-title-type="left-running-head">G. J. Stephens</alt-title><alt-title alt-title-type="right-running-head">The endocannabinoid system in cerebellar ataxia</alt-title></title-group><contrib-group><contrib id="tjp7198-cr-0001" contrib-type="author" corresp="yes"><name><surname>Stephens</surname><given-names>G. J.</given-names></name><xref ref-type="aff" rid="tjp7198-aff-0001">
<sup>1</sup>
</xref><xref ref-type="bio" rid="d36e56">*</xref></contrib></contrib-group><aff id="tjp7198-aff-0001"><label><sup>1</sup></label><named-content content-type="organisation-division">School of Pharmacy</named-content><institution>University of Reading</institution><named-content content-type="city">Reading</named-content><named-content content-type="post-code">RG6 6AJ</named-content><country country="GB">UK</country></aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Corresponding authors</bold> G. J. Stephens: School of Pharmacy, University of Reading, Whiteknights, Reading RG6 6AJ, UK. Email: <email>g.j.stephens@reading.ac.uk</email></corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>6</month><year>2016</year></pub-date><pub-date pub-type="ppub"><day>15</day><month>8</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>08</day><month>6</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>594</volume><issue>16</issue><issue-id pub-id-type="doi">10.1113/tjp.2016.594.issue-16</issue-id><fpage>4631</fpage><lpage>4641</lpage><history><date date-type="received"><day>14</day><month>6</month><year>2015</year></date><date date-type="accepted"><day>04</day><month>2</month><year>2016</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Journal compilation &#x000a9; 2016 The Physiological Society <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2016 The Authors. The Journal of Physiology published by John Wiley &#x00026; Sons Ltd on behalf of The Physiological Society</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:TJP-594-4631.pdf"/><abstract><title>Abstract</title><p>Cerebellar ataxias represent a spectrum of disorders which are, however, linked by common symptoms of motor incoordination and typically associated with deficiency in Purkinje cell firing activity and, often, degeneration. Cerebellar ataxias currently lack a curative agent. The endocannabinoid (eCB) system includes eCB compounds and their associated metabolic enzymes, together with cannabinoid receptors, predominantly the cannabinoid CB<sub>1</sub> receptor (CB<sub>1</sub>R) in the cerebellum; activation of this system in the cerebellar cortex is associated with deficits in motor coordination characteristic of ataxia, effects which can be prevented by CB<sub>1</sub>R antagonists. Of further interest are various findings that CB<sub>1</sub>R deficits may also induce a progressive ataxic phenotype. Together these studies suggest that motor coordination is reliant on maintaining the correct balance in eCB system signalling. Recent work also demonstrates deficient cannabinoid signalling in the mouse &#x02018;ducky<sup>2J</sup>&#x02019; model of ataxia. In light of these points, the potential mechanisms whereby cannabinoids may modulate the eCB system to ameliorate dysfunction associated with cerebellar ataxias are considered.
<boxed-text position="anchor" content-type="graphic" orientation="portrait"><graphic xlink:href="TJP-594-4631-g003.jpg" position="anchor" id="nlm-graphic-3" orientation="portrait"/></boxed-text>
</p></abstract><counts><page-count count="11"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>tjp7198</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>15 August 2016</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:4.9.4 mode:remove_FC converted:14.08.2016</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group><fn id="tjp7198-note-0001"><p>This review was presented at the symposium &#x0201c;Mechanisms of cerebellar ataxias and neurodegeneration&#x0201d;, which took place at Ageing and Degeneration: A Physiological Perspective in Edinburgh, UK, 10&#x02013;11 April 2015.</p></fn></fn-group></notes></front><body><def-list list-content="abbreviations" id="tjp7198-lp-0001"><title>Abbreviations</title><def-item><term>2&#x02010;AG</term><def><p>2&#x02010;arachidonylglycerol</p></def></def-item><def-item><term>CBD</term><def><p>cannabidiol</p></def></def-item><def-item><term>CBDV</term><def><p>cannabidivarin</p></def></def-item><def-item><term>CF</term><def><p>climbing fibre</p></def></def-item><def-item><term>eCB</term><def><p>endocannabinoid</p></def></def-item><def-item><term>GPCR</term><def><p>G protein&#x02010;coupled receptor</p></def></def-item><def-item><term>IN</term><def><p>interneuron</p></def></def-item><def-item><term>LTD</term><def><p>long term depression</p></def></def-item><def-item><term>MAGL</term><def><p>monoacylglycerol lipase</p></def></def-item><def-item><term>PC</term><def><p>Purkinje cell</p></def></def-item><def-item><term>pCB</term><def><p>phytocannabinoid</p></def></def-item><def-item><term>PF</term><def><p>parallel fibre</p></def></def-item><def-item><term>SCA</term><def><p>spinocerebellar ataxia</p></def></def-item><def-item><term>&#x00394;<sup>9</sup>&#x02010;THC</term><def><p>tetrahydrocannabinol</p></def></def-item><def-item><term>VDCC</term><def><p>voltage&#x02010;dependent Ca<sup>2+</sup> channel</p></def></def-item></def-list><sec disp-level="2" id="tjp7198-sec-0020"><title>Cerebellar ataxias are a diverse group of disorders lacking a therapeutic agent</title><p>Cerebellar ataxias comprise a group of progressive neurological diseases associated with deficits in motor coordination and are typically associated with dysfunction and/or degeneration of Purkinje cells (PCs), the sole efferent output of the cerebellar cortex. There are a range of acquired ataxias and different hereditary forms of the disease (Klockgether, <xref rid="tjp7198-bib-0039" ref-type="ref">2011</xref>). Thus, ataxia can be acquired from, amongst others, traumatic head injury, bacterial infection (meningitis or encephalitis), viral infection (chickenpox or measles), disruption of blood flow (stroke or transient ischaemic attack, haemorrhage), CNS disease (cerebral palsy or multiple sclerosis), sustained long&#x02010;term alcohol misuse, underactive thyroid gland and cancer autoimmune conditions (lupus), and can also be iatrogenic. Hereditary ataxias may be autosomal&#x02010;dominant diseases, including forms of spinocerebellar ataxia (SCA), several of which are associated with polyglutamine repeats in the dysfunctional protein; for example: ataxin 1 in SCA1; ataxin 2 in SCA2; Cacna1a encoding the voltage&#x02010;dependent Ca<sup>2+</sup> channel (VDCC) Ca<sub>V</sub>2.1 subunit in SCA6 (also in episodic ataxia 2). There are also autosomal&#x02010;recessive diseases such as Friedreich's ataxia and ataxia telangiectasia associated with deficits in, respectively, the mitochondrial protein frataxin and a serine/threonine protein kinase termed ataxia telangiectasia mutated protein (Klockgether, <xref rid="tjp7198-bib-0039" ref-type="ref">2011</xref>). Despite this range of causes and implicated proteins, deleterious effects are largely limited to the cerebellar cortex and are typically associated with cerebellar dysfunction and/or degeneration and are manifest as motor incoordination. This commonality of symptoms offers hope for providing treatment options; however, at present there is no known cure for cerebellar ataxia. There are treatments to ameliorate associated symptoms. For example, vitamin E and anti&#x02010;oxidants, such as co&#x02010;enzyme Q10 and its synthetic analogue idebenone, have been suggested to have some benefit, largely in Friedreich ataxia. However, as yet, such agents lack proven efficacy in controlled clinical trials (Cooper <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0011" ref-type="ref">2008</xref>; Lynch <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0047" ref-type="ref">2010</xref>), although some improvement in comparison to controls was seen in cross&#x02010;over trials, suggesting that patients with vitamin E&#x02010;deficient and co&#x02010;enzyme Q10&#x02010;deficient ataxia may receive some benefit (Cooper <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0011" ref-type="ref">2008</xref>). In addition, administration of thyrotropin&#x02010;releasing hormone (TRH) was reported to ameliorate cerebellar ataxia in rolling Nagoya mice (Shibusawa <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0068" ref-type="ref">2008</xref>) and the TRH analogue taltirelin is approved to improve motor performance in ataxic patients in Japan.</p><p>The elucidation of function of proteins associated with inherited ataxias within the cerebellar cortex may also lead to future therapeutic advances relevant across different forms of ataxia. Amongst target proteins, the Ca<sub>V</sub>2.1 (&#x003b1;1A) VDCC represents a widely studied protein. Ca<sub>V</sub>2.1 subunits are highly expressed in the cerebellum (Westenbroek <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0085" ref-type="ref">1995</xref>; Kulik <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0042" ref-type="ref">2004</xref>). In particular, Ca<sub>V</sub>2.1 is expressed postsynaptically in PCs (which led to the designation of these subunits as carriers of P&#x02010;type Ca<sup>2+</sup> current (Mintz <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0056" ref-type="ref">1992</xref>)), at presynaptic terminals of inhibitory interneurons (INs) arising from basket and stellate cells, and of excitatory, parallel fibres (PFs) and climbing fibres (CFs); such inputs regulate PC, and thus cerebellar cortex, output activity (Regehr &#x00026; Mintz, <xref rid="tjp7198-bib-0066" ref-type="ref">1994</xref>; Mintz <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0055" ref-type="ref">1995</xref>; Stephens <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0073" ref-type="ref">2001</xref>; Lonchamp <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0046" ref-type="ref">2009</xref>). Several mouse Ca<sub>V</sub>2.1 mutants display ataxia (Pietrobon, <xref rid="tjp7198-bib-0061" ref-type="ref">2010</xref>; Rajakulendran <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0063" ref-type="ref">2012</xref>). Correspondingly, genetic deletion of Ca<sub>V</sub>2.1 is associated with a clear ataxic behavioural phenotype (Jun <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0033" ref-type="ref">1999</xref>). Moreover, conditional PC&#x02010;specific Ca<sub>V</sub>2.1 knock&#x02010;down was shown to be sufficient to induce impaired synaptic transmission and ataxia (Mark <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0051" ref-type="ref">2011</xref>; Todorov <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0079" ref-type="ref">2012</xref>), the former study termed their mice &#x02018;purky&#x02019;. Cell&#x02010;specific work was extended to excitatory inputs into PCs, where it was shown that selective Ca<sub>V</sub>2.1 knockdown in PFs (arising from mossy fibre inputs) in so&#x02010;called &#x02018;quirky&#x02019; mice, also gave rise to an ataxic phenotype (Maejima <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0050" ref-type="ref">2013</xref>). Of further interest here, is that mutations which <italic>increase</italic> Ca<sub>V</sub>2.1 current also give impaired synaptic transmission and irregular PC firing (a cerebellar epitome predicted to lead to motor incoordination) (Gao <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0022" ref-type="ref">2012</xref>); these reports suggest that correct VDCC activity must be maintained for PC firing fidelity. To add to purky and quirky, we also have &#x02018;ducky&#x02019; mice (Barclay <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0004" ref-type="ref">2001</xref>). Ducky, and the related ducky<sup>2J</sup> (<italic>du<sup>2J</sup></italic>) strain, have mutations predicted to lead to deficits in &#x003b1;2&#x003b4;&#x02010;2 auxiliary VDCC subunit protein, which is expressed at high levels in normal cerebella (Cole <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0010" ref-type="ref">2005</xref>) and is associated predominantly with Ca<sub>V</sub>2.1 in the cerebellum (Barclay <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0004" ref-type="ref">2001</xref>). In different ducky strains, the ataxic phenotype is associated with a reduction in postsynaptic PC whole&#x02010;cell Ca<sup>2+</sup> current (Brodbeck <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0006" ref-type="ref">2002</xref>; Donato <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0016" ref-type="ref">2006</xref>), together with irregular PC firing (Donato <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0016" ref-type="ref">2006</xref>; Walter <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0082" ref-type="ref">2006</xref>; Wang <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0084" ref-type="ref">2013</xref>). Thus, several potential therapeutic targets have been suggested, largely confined to protein associated with inherited ataxias; however, as discussed above, as yet we have no cure for ataxia. The remainder of this review will focus on the potential to target the endocannabinoid (eCB) system to ameliorate cerebellar ataxia and, in particular, eCB compounds and their associated metabolic enzymes and G protein&#x02010;coupled CB<sub>1</sub>R, one of the most ubiquitously expressed proteins in the mammalian cerebellum, and a protein which also modulates Ca<sub>V</sub>2.1 activity at the presynapse.</p></sec><sec disp-level="2" id="tjp7198-sec-0030"><title>Cannabinoid signalling and its potential links to cerebellar ataxia</title><p>Cannabinoids represent a diverse number of compounds, including (i) eCBs, for example, the lipid mediator 2&#x02010;arachidonylglycerol (2&#x02010;AG), which is the major eCB in the cerebellum (Szabo <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0075" ref-type="ref">2006</xref>); (ii) plant&#x02010;derived phytocannabinoids (pCBs), for example, the major herbal <italic>Cannabis</italic> constituents tetrahydrocannabinol (&#x00394;<sup>9</sup>&#x02010;THC) and cannabidiol (CBD) (Hill <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0027" ref-type="ref">2012</xref>
<italic>a</italic>); and (iii) exogenous synthetic agents, namely CB<sub>1</sub>R agonists, for example, WIN 55,212&#x02010;2, an aminoalkylindole derivative, and CP 55940, which is structurally related to tetrahydrocannabinol, and CB<sub>1</sub>R antagonists/inverse agonists, for example, rimonabant (Pertwee <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0060" ref-type="ref">2010</xref>), and newer allosteric modulators, for example, Org27569 (Price <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0062" ref-type="ref">2005</xref>) and PSNCBAM&#x02010;1 (Horswill <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0030" ref-type="ref">2007</xref>).</p><p>Within the CNS, cannabinoids predominantly activate CB<sub>1</sub>Rs, which represent the most widespread G protein&#x02010;coupled receptor (GPCR) in the mammalian cerebellum (Herkenham <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0025" ref-type="ref">1991</xref>; Tsou <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0080" ref-type="ref">1997</xref>). CB<sub>1</sub>R expression is reported to be very low at PC cell bodies; rather, expression is high at excitatory PF inputs into PCs, reportedly with a perisynaptic over extrasynaptic and synaptic localization, with lower CB<sub>1</sub>R expression at CF inputs onto PC dendritic shafts (Kawamura <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0036" ref-type="ref">2006</xref>; see Abstract Figure). CB<sub>1</sub>Rs are expressed at higher levels on presynaptic terminals of inhibitory INs, predominantly basket cells, but also stellate cells, which form a specialized region surrounding the PC axon initial segment known as the pinceau (the French word for paintbrush) (Tsou <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0080" ref-type="ref">1997</xref>; Kawamura <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0036" ref-type="ref">2006</xref>; Rodr&#x000ed;guez&#x02010;Cueto <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0064" ref-type="ref">2014</xref>). Presynaptic CB<sub>1</sub>Rs are activated by retrograde &#x02018;on demand&#x02019; release of 2&#x02010;AG from postsynaptic PCs. The major effect of presynaptic CB<sub>1</sub>R activation is a suppression of neurotransmitter release, whereby activation of presynaptic CB<sub>1</sub>Rs inhibits action potential&#x02010;evoked and spontaneous inhibitory postsynaptic currents (IPSCs) at IN&#x02013;PC synapses (see Fig. <xref rid="tjp7198-fig-0001" ref-type="fig">1</xref>) or excitatory postsynaptic currents (EPSCs) at PF&#x02013;PC and CF&#x02013;PC synapses (Takahashi &#x00026; Linden, <xref rid="tjp7198-bib-0076" ref-type="ref">2000</xref>; Szabo <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0074" ref-type="ref">2004</xref>; Kano <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0035" ref-type="ref">2009</xref>). We have also used multi&#x02010;electrode array recording to demonstrate that CB<sub>1</sub>R ligand&#x02010;induced changes to cerebellar cortex network activity are mediated, at least in part, via effects on inhibitory synaptic transmission (Ma <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0048" ref-type="ref">2008</xref>). CB<sub>1</sub>R activation has been widely associated with a number of different forms of short&#x02010; and long&#x02010;term synaptic plasticities which modulate cerebellar learning (Kano <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0035" ref-type="ref">2009</xref>; Ohno&#x02010;Shosaku &#x00026; Kano, <xref rid="tjp7198-bib-0058" ref-type="ref">2014</xref>). Thus, 2&#x02010;AG release mediates the short&#x02010;term suppression of inhibitory GABA release from IN terminals (depolarization&#x02010;induced suppression of inhibition) or excitatory glutamate release (depolarization&#x02010;induced suppression of excitation) (Szabo <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0075" ref-type="ref">2006</xref>; Tanimura <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0077" ref-type="ref">2009</xref>). Seminal work by Ito (<xref rid="tjp7198-bib-0032" ref-type="ref">1989</xref>) linked long term depression (LTD) by associative stimulation of PF and CF inputs to PCs, to motor learning in the cerebellum. It is also known that the metabotropic glutamate receptor 1 (mGluR1) pathway is critically involved in cerebellar development and LTD (Aiba <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0001" ref-type="ref">1994</xref>), and it was further proposed that CF inputs into individual PCs were required for normal motor coordination (Chen <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0008" ref-type="ref">1995</xref>). More recent work has established that cerebellar LTD is a postsynaptic phenomenon requiring 2&#x02010;AG release from PCs and activation of presynaptic CB<sub>1</sub>Rs at PF&#x02013;PC synapses (Safo &#x00026; Regehr, <xref rid="tjp7198-bib-0067" ref-type="ref">2005</xref>). Here, mGluR1 activation drives 2&#x02010;AG release (Kano <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0035" ref-type="ref">2009</xref>; see Abstract Figure). Thus, CB<sub>1</sub>Rs have a privileged position in the function and control of overall output of the cerebellar cortex and, as such, represent good potential targets to modulate dysfunctional signalling associated with cerebellar ataxias.</p><fig fig-type="Figure" xml:lang="en" id="tjp7198-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><title>
<bold>Presynaptic CB<sub>1</sub>R modulation of inhibitory transmission at IN&#x02013;PC synapses is deficient in ataxic ducky<sup>2J</sup> mice</bold>
</title><p>
<italic>Aa</italic> and <italic>Ba</italic>, representative spontaneous inhibitory postsynaptic current (sIPSC) traces from +/+ (<italic>Aa</italic>) and <italic>du<sup>2J</sup>/du<sup>2J</sup></italic> (<italic>Ba</italic>) PCs showing effect of WIN55 (5&#x000a0;&#x003bc;<sc>m</sc>), and also subsequent application of AM251 (2&#x000a0;&#x003bc;<sc>m</sc>). <italic>Ab</italic> and <italic>Bb</italic>, summary bar graphs showing that WIN55 significantly reduced, and AM251 significantly increased, normalized sIPSC frequency in +/+ (<italic>Ab</italic>), but was without effect in <italic>du<sup>2J</sup>/du<sup>2J</sup></italic> (<italic>Bb</italic>), conditions. <sup>*</sup>
<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05; <sup>**</sup>
<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.01; repeated measurement one&#x02010;way ANOVA followed by Tukey's honest significant difference test. <italic>Ac</italic> and <italic>Bc</italic>, summary diagrams for +/+ (<italic>Ac</italic>) and <italic>du<sup>2J</sup>/du<sup>2J</sup></italic> (<italic>Bc</italic>) conditions. <italic>Ad</italic>, in wild&#x02010;type conditions, CB<sub>1</sub>R activation (i.e. +WIN55) causes the release of G&#x003b2;&#x003b3; subunit from CB<sub>1</sub>R and subsequent inhibitory coupling of G&#x003b2;&#x003b3; to Cav2.1 at the presynapse to inhibit the action potential&#x02010;evoked GABA release seen in control (CTL). <italic>Bd</italic>, by contrast, in <italic>du<sup>2J</sup>/du<sup>2J</sup></italic> conditions, CB<sub>1</sub>R activation (i.e. +WIN55) has no effect on the GABA release seen in control (CTL). AM251 effects were also absent (see Wang <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0084" ref-type="ref">2013</xref>). Thus, we propose that at synapses lacking &#x003b1;2&#x003b4;&#x02010;2 subunits (which associate predominantly with Ca<sub>V</sub>2.1 in the cerebellum; Barclay <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0004" ref-type="ref">2001</xref>), normal CB<sub>1</sub>R modulation of Ca<sub>V</sub>2.1 is lacking. This deficit may relate to incorrect control of synaptic release by &#x003b1;2&#x003b4; subunits (Hoppa <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0029" ref-type="ref">2012</xref>); alternatively, it is possibly that lack of &#x003b1;2&#x003b4; subunits may cause changes to CB<sub>1</sub>R&#x02010;mediated G protein inhibition of Ca<sub>V</sub>2.1.</p></caption><graphic id="nlm-graphic-7" xlink:href="TJP-594-4631-g002"/></fig><p>In cell lines and native neurons, CB<sub>1</sub>R activation causes pertussis toxin&#x02010;sensitive inhibition of Ca<sub>V</sub>2 family VDCCs, and can also activate inwardly rectifier K<sup>+</sup> channels (Mackie &#x00026; Hille, <xref rid="tjp7198-bib-0049" ref-type="ref">1992</xref>; Twitchell <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0081" ref-type="ref">1997</xref>; Guo &#x00026; Ikeda, <xref rid="tjp7198-bib-0023" ref-type="ref">2004</xref>). It is likely that CB<sub>1</sub>Rs couple to presynaptic Ca<sub>V</sub>2.1 (P/Q&#x02010;type) VDCCs at IN&#x02013;PC synapses to reduce action potential evoked GABA release (Forti <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0019" ref-type="ref">2000</xref>; Stephens <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0073" ref-type="ref">2001</xref>; Lonchamp <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0046" ref-type="ref">2009</xref>) and to Ca<sub>V</sub>2.1 (and to a lesser extent Ca<sub>V</sub>2.2 and Ca<sub>V</sub>2.3) at PF&#x02013;PC synapses to reduce action potential&#x02010;evoked glutamate release (Brown <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0007" ref-type="ref">2004</xref>); these effects are most likely mediated by direct binding of G protein G&#x003b2;&#x003b3; subunits to VDCCs (Abstract Figure and Fig. <xref rid="tjp7198-fig-0001" ref-type="fig">1</xref>).</p><p>CB<sub>1</sub>R agonists also cause clear reductions in frequency of &#x02018;miniature&#x02019; IPSCs at IN&#x02013;PC synapses (Takahashi &#x00026; Linden, <xref rid="tjp7198-bib-0076" ref-type="ref">2000</xref>; Yamasaki <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0086" ref-type="ref">2006</xref>; Ma <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0048" ref-type="ref">2008</xref>), consistent with an inhibition of action potential&#x02010;independent GABA release. These effects are proposed to occur downstream of actions on voltage&#x02010;dependent ion channels and are also consistent with direct effects on the synaptic release machinery, and also may be mediated by G&#x003b2;&#x003b3; subunits (Stephens, <xref rid="tjp7198-bib-0072" ref-type="ref">2009</xref>). By contrast, CB<sub>1</sub>R agonist effects on miniature EPSCs at PF&#x02013;PC synapses were only apparent when extracellular Ca<sup>2+</sup> levels were increased (Yamasaki <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0086" ref-type="ref">2006</xref>). Moreover, CB<sub>1</sub>R antagonists/inverse agonists such as AM251, rimonabant and the pCB &#x00394;<sup>9</sup>&#x02010;tetrahydrocannabivarin all increase inhibitory GABA release at IN&#x02013;PC synapses (Ma <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0048" ref-type="ref">2008</xref>). Such effects are consistent with the presence of a strong, modulatable eCB tone in the cerebellum (Kreitzer <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0041" ref-type="ref">2002</xref>; Galante &#x00026; Diana, <xref rid="tjp7198-bib-0020" ref-type="ref">2004</xref>), which provides further opportunity for therapeutic intervention in cerebellar ataxia.</p><p>Importantly, activation of presynaptic CB<sub>1</sub>Rs by synthetic cannabinoids and eCBs has been shown to promote cerebellar dysfunction, causing severe motor incoordination and modelling cerebellar ataxia (Lichtman <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0045" ref-type="ref">1998</xref>; DeSanty &#x00026; Dar, <xref rid="tjp7198-bib-0012" ref-type="ref">2001</xref>; Patel &#x00026; Hillard, <xref rid="tjp7198-bib-0059" ref-type="ref">2001</xref>); in these studies pre&#x02010;treatment with a CB<sub>1</sub>R antagonist or CB<sub>1</sub>R antisense prevented the induction of an ataxic phenotype. Such data suggest that CB<sub>1</sub>R antagonism may be useful in the pathogenic situation. In comparison to administration of CB<sub>1</sub>R ligands, data with CB<sub>1</sub>R knock&#x02010;out mice are somewhat more equivocal. Thus, young/mature CB<sub>1</sub>R deficient mice are reported not to exhibit clear motor discoordination or changes to gait (Steiner <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0070" ref-type="ref">1999</xref>; Kishimoto &#x00026; Kano, <xref rid="tjp7198-bib-0038" ref-type="ref">2006</xref>); however, deficits in motor function were reported in mature and older mice, in comparison to unaffected younger mice, in rotarod tests (Bilkei&#x02010;Gorzo <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0005" ref-type="ref">2005</xref>). One interpretation of these studies is that a progressive ataxic pathogenesis may be associated with long&#x02010;term loss of CB<sub>1</sub>R. One common feature of CB<sub>1</sub>R knock&#x02010;out mice, chronic marijuana users or animals administered CB<sub>1</sub>R agonists is a reported deficit in delay eyeblink conditioning, a cerebellar&#x02010;dependent, motor learning process (Kishimoto &#x00026; Kano, <xref rid="tjp7198-bib-0038" ref-type="ref">2006</xref>; Skosnik <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0069" ref-type="ref">2008</xref>; Steinmetz &#x00026; Freeman, <xref rid="tjp7198-bib-0071" ref-type="ref">2010</xref>). These data are consistent with CB<sub>1</sub>R controlling discrete motor function. Kishimoto &#x00026; Kano (<xref rid="tjp7198-bib-0038" ref-type="ref">2006</xref>) also report that pharmacological block of CB<sub>1</sub>R had no effect on motor function in wild&#x02010;type mice; however, it is also important to point out that CB<sub>1</sub>R deficiency and/or lack of effect of CB<sub>1</sub>R antagonism in a non&#x02010;pathogenic situation does not preclude a role in disease; for example, whilst SR141617A (rimonabant) reversed CB<sub>1</sub>R&#x02010;induced dysfunction, it had no effects itself on motor incoordination in non&#x02010;ataxic animals (Lichtman <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0045" ref-type="ref">1998</xref>; DeSanty &#x00026; Dar, <xref rid="tjp7198-bib-0012" ref-type="ref">2001</xref>). Together, these data suggest that CB<sub>1</sub>Rs modulate cerebellar circuitry in ataxic disease, potentially with a progressive onset of effect. Therefore, targeting CB<sub>1</sub>Rs may be beneficial in modulating motor incoordination in cerebellar ataxia, as discussed more fully below.</p></sec><sec disp-level="2" id="tjp7198-sec-0040"><title>An ataxic mouse model has deficient CB<sub>1</sub>R signalling</title><p>Whilst the role of ion channels (in particular, Ca<sub>V</sub>2.1) has been broadly studied in animal models of ataxia, there has been much less work on the presynaptic receptors that modulate neurotransmitter release and the postsynaptic receptors responsible for onward signalling in such models. A study in Ca<sub>V</sub>2.1 mutant tottering mice by Zhou and co&#x02010;workers reported that presynaptic inhibition mediated by GABA<sub>B</sub> or &#x003b1;2&#x02010;adrenoceptor GPCRs was enhanced at excitatory PF&#x02013;PC synapses, although this may be as consequence of a switch to a reliance on Ca<sub>V</sub>2.2 (N&#x02010;type) channels for transmitter release (Zhou <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0088" ref-type="ref">2003</xref>). Tottering mice also had a reduction in GABA<sub>A</sub> receptor expression, with specific deficits in granule cells (Kaja <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0034" ref-type="ref">2007</xref>). We have shown that ataxic <italic>du<sup>2J</sup></italic> mutant mice exhibit increased irregularity of PC and, to a lesser extent, granule cell firing in multi&#x02010;electrode array recordings from cerebellar brain slices (Wang <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0084" ref-type="ref">2013</xref>). Of note, clear effects on PC firing regularity in <italic>du<sup>2J</sup></italic>/<italic>du<sup>2J</sup></italic> mice were not seen in heterozygous +/<italic>du<sup>2J</sup></italic> mice, and the latter also lacked a clear behavioural ataxic phenotype. Importantly, the CB<sub>1</sub>R&#x02010;mediated inhibition at IN&#x02013;PC synapses seen in litter&#x02010;matched controls was completely absent in both +/<italic>du<sup>2J</sup></italic> and <italic>du<sup>2J</sup></italic>/<italic>du<sup>2J</sup></italic> mice. These data demonstrate that ataxic &#x003b1;2&#x003b4;&#x02010;2&#x02010;deficient mice have aberrant presynaptic CB<sub>1</sub>R&#x02010;mediated signalling. The question arises as to whether deficiency in CB<sub>1</sub>R&#x02010;mediated signalling is involved in ataxia pathogenesis or whether it occurs as a result of the disease. It appears that, in this model, both alleles need to be affected in order for an ataxic phenotype to be seen (Wang <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0084" ref-type="ref">2013</xref>), and thus progressive deficits may be associated with <italic>du<sup>2J</sup></italic> mice. We saw no changes in PC firing regularity in response to CB<sub>1</sub>R ligands in wild&#x02010;type or <italic>du<sup>2J</sup></italic> mice, consistent with a lack of postsynaptic CB<sub>1</sub>R effects in this model. We propose that such deficits occur due to compromised Ca<sup>2+</sup> channel activity consequent to reduced presynaptic &#x003b1;2&#x003b4;&#x02010;2 expression in <italic>du<sup>2J</sup></italic> mice (Fig. <xref rid="tjp7198-fig-0001" ref-type="fig">1</xref>). In this regard, &#x003b1;2&#x003b4;&#x02010;2 subunits have been shown to be essential not only for Ca<sup>2+</sup> channel trafficking (Dolphin, <xref rid="tjp7198-bib-0015" ref-type="ref">2012</xref>), but also for synaptic function, the latter by increasing transmitter release probability and also protecting release from inhibitory effects of intracellular Ca<sup>2+</sup> chelators (Hoppa <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0029" ref-type="ref">2012</xref>).</p><p>There are few studies measuring CB<sub>1</sub>R expression in ataxic animals; we reported no clear changes in expression in the cerebellar cortex of +/<italic>du<sup>2J</sup></italic> and <italic>du<sup>2J</sup></italic>/<italic>du<sup>2J</sup></italic> mice (Wang <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0084" ref-type="ref">2013</xref>). In a recent study, post&#x02010;mortem cerebellar tissue from patients with SCAs, CB<sub>1</sub>R (and CB<sub>2</sub>R) expression was generally up&#x02010;regulated in PCs, and also in glial cells (Rodr&#x000ed;guez&#x02010;Cueto <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0064" ref-type="ref">2014</xref>
<italic>a</italic>). Of interest here was that CB<sub>1</sub>R expression was reported in PC soma and pinceau in SCA patients, but was confined largely to the pinceau in control patients. It is possible that upregulated postsynaptic CB<sub>1</sub>R expression may affect 2&#x02010;AG release in SCA patients; however, Rodriguez&#x02010;Cueto and co&#x02010;workers suggest that this CB<sub>1</sub>R expression is associated with degenerating PCs and may represent a marker for degeneration and/or a protective response against such degeneration. A further study in SCA patients reported an up&#x02010;regulation of eCB degradative fatty acid amide hydrolase and monoacylglycerol lipase (MAGL) enzymes (Rodr&#x000ed;guez&#x02010;Cueto <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0065" ref-type="ref">2014</xref>
<italic>b</italic>), proposed to lead to reduced eCB levels in disease. In these studies, a compensatory up&#x02010;regulation of cannabinoid receptor expression may occur as a consequence of reduced eCB levels; alternatively, it may be argued that eCBs are suppressed in order not to overactivate the system. Thus, it may also be possible to target eCB metabolizing enzymes for future therapeutic development. In this regard, potential avenues to increase 2&#x02010;AG include inhibition of MAGL, localized predominantly to the PF terminal (Tanimura <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0078" ref-type="ref">2012</xref>), or activation of the biosynthetic enzyme diacylglycerol lipase&#x02010;&#x003b1; (DAGL&#x003b1;) localized predominantly to the base of postsynaptic dendritic spines (Yoshida <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0087" ref-type="ref">2006</xref>) (see Abstract Figure). It is also clear that we will need to investigate potential changes to eCB signalling in different animal models of ataxia to inform development of the most useful therapeutic strategies and also to determine if any such changes represent useful markers for different forms of ataxia.</p></sec><sec disp-level="2" id="tjp7198-sec-0050"><title>Do cannabinoids have therapeutic utility in cerebellar ataxia?</title><p>There are anecdotal reports that cannabis smokers can achieve symptom relief for several CNS disorders. Such evidence has fuelled the investigation of use of CB<sub>1</sub>R agonists as potential neuroprotective agents for a range of conditions including epilepsy, neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's disease and appetitive disorders (Fern&#x000e1;ndez&#x02010;Ruiz <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0018" ref-type="ref">2011</xref>; Hill <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0027" ref-type="ref">2012</xref>
<italic>a</italic>). Earlier evidence for ataxia is largely confined to two case studies which suggest that oral &#x00394;<sup>9</sup>&#x02010;THC or marijuana improved motor coordination in some multiple sclerosis patients (Clifford, <xref rid="tjp7198-bib-0009" ref-type="ref">1983</xref>; Meinck <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0053" ref-type="ref">1989</xref>). At the clinical level, synthetic &#x00394;<sup>9</sup>&#x02010;THC has been used in management of nausea, emesis and pain, and nabiximols (Sativex) (containing &#x0223c;1:1 &#x00394;<sup>9</sup>&#x02010;THC:CBD) represents the first phytocannabinoid medicine, used as an oromucosal spray for pain and spasticity associated with multiple sclerosis (Hill <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0027" ref-type="ref">2012</xref>
<italic>a</italic>); Sativex was also stated to delay onset of ataxia symptoms in the Medicines and Healthcare products Regulatory Agency (MHRA) Public Information Report UK/H/961/01/DC. Such reports contributed to fuelling a major review on the clinical effects of cannabinoids in ataxia associated with multiple sclerosis (Mills <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0054" ref-type="ref">2007</xref>); although cannabinoids showed promise, it was concluded that better standardized measures of ataxia were needed to fully establish the utility of cannabis&#x02010;based medicines in ataxia. The role of cannabinoids in disease&#x02010;associated movement disorders and tremor has been further discussed more recently by Arjmand <italic>et&#x000a0;al</italic>. (<xref rid="tjp7198-bib-0002" ref-type="ref">2015</xref>) and Kluger <italic>et&#x000a0;al</italic>. (<xref rid="tjp7198-bib-0040" ref-type="ref">2015</xref>), who similarly concluded that further work on cannabinoids in different models of ataxia is warranted. In this regard, an interesting recent report suggests that a &#x02018;Sativex&#x02010;like&#x02019; combination of &#x00394;<sup>9</sup>&#x02010;THC and CBD, as well as the individual administration of &#x00394;<sup>9</sup>&#x02010;THC or CBD, was able to improve motor deficits in a viral model of multiple sclerosis (Feli&#x000fa; <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0017" ref-type="ref">2015</xref>). Clearly, studies which suggest CB<sub>1</sub>R activation may be useful in cerebellar ataxia contrast to preclinical data where CB<sub>1</sub>R agonists induce an ataxic phenotype (Lichtman <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0045" ref-type="ref">1998</xref>; DeSanty &#x00026; Dar, <xref rid="tjp7198-bib-0012" ref-type="ref">2001</xref>; Patel &#x00026; Hillard, <xref rid="tjp7198-bib-0059" ref-type="ref">2001</xref>); however, these data do support the hypothesis that maintaining the correct balance in eCB system signalling is a major factor for proper control of motor coordination. This hypothesis is further supported by data from Ca<sub>V</sub>2.1 mutants described above, where both decreases (Maejima <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0050" ref-type="ref">2013</xref>) and increases in Ca<sup>2+</sup> current (Gao <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0022" ref-type="ref">2012</xref>) can produce an ataxia phenotype; moreover, deficits in delay eyeblink conditioning are reported for both CB<sub>1</sub>R agonists and CB<sub>1</sub>R antagonists/inverse agonists using the same experimental design (Steinmetz &#x00026; Freeman, <xref rid="tjp7198-bib-0071" ref-type="ref">2010</xref>). CB<sub>1</sub>R agonists have also been shown to possess functional selectively or &#x02018;biased agonism&#x02019;, whereby different ligands (including eCBs) preferentially activate different CB<sub>1</sub>R signalling pathways (Laprairie <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0044" ref-type="ref">2014</xref>; Khajehali <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0037" ref-type="ref">2015</xref>). Whilst, as argued above, it is likely that CB<sub>1</sub>Rs act predominantly on presynaptic Ca<sub>V</sub>2.1 to reduce transmitter release in the cerebellar cortex, alternative signalling pathways include inhibition of cAMP or stimulation of phosphorylation of signal regulated kinases (Howlett <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0031" ref-type="ref">2010</xref>). Thus, it could be argued that by using knowledge of biased agonism that we can target specific pathways associated with diseases, including cerebellar ataxia. Finally here, CB<sub>1</sub>R agonists such as &#x00394;<sup>9</sup>&#x02010;THC have also been proposed to possess anti&#x02010;oxidant (Hampson <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0024" ref-type="ref">1998</xref>) and anti&#x02010;inflammatory (although largely CB<sub>2</sub>R&#x02010;mediated) (Fern&#x000e1;ndez&#x02010;Ruiz <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0018" ref-type="ref">2011</xref>) properties; in common with other degenerative diseases, such properties may benefit the amelioration of cerebellar ataxia symptoms.</p><p>The demonstration that pre&#x02010;treatment with a CB<sub>1</sub>R antagonist prevents the induction of motor incoordination by CB<sub>1</sub>R agonists (DeSanty &#x00026; Dar, <xref rid="tjp7198-bib-0012" ref-type="ref">2001</xref>; Patel &#x00026; Hillard, <xref rid="tjp7198-bib-0059" ref-type="ref">2001</xref>) suggests that CB<sub>1</sub>R antagonists/inverse agonists may be protective in ataxia. The archetypal agent rimonabant was introduced as an anti&#x02010;obesity agent, but was withdrawn due to fears of increased suicidality and depression in patients (Nathan <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0057" ref-type="ref">2011</xref>). Since then, therapeutic development of CB<sub>1</sub>R antagonists/inverse agonists has largely been put on hold. Interesting potential alternatives are CB<sub>1</sub>R negative allosteric antagonists, such as Org&#x02010;27569 and PSNCBAM&#x02010;1. These compounds have a somewhat unique pharmacological profile as they increase orthosteric agonist binding, but decrease agonist activity; more intriguingly, allosteric antagonism action is ligand&#x02010;dependent and also shows biased antagonism for different signalling pathways (Baillie <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0003" ref-type="ref">2013</xref>). We have shown that such functional selectivity for PSNCBAM&#x02010;1 extends to effects on orthosteric ligands at IN&#x02013;PC synapses in the cerebellar cortex (Wang <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0083" ref-type="ref">2011</xref>); thus, PSNCBAM&#x02010;1 attenuated CP55940 agonist and AM251 antagonist effects, but had no clear effects against WIN 55,212&#x02010;2. Moreover, when applied alone, PSNCBAM&#x02010;1 was not associated with potentially deleterious effects on eCB tone, a concern associated with use of CB<sub>1</sub>R antagonists/inverse agonists such as rimonabant. These studies indicate that exogenous allosteric CB<sub>1</sub>R ligands have potential to fine tune eCB orthosteric agonist effects in a ligand&#x02010; and/or cell signalling&#x02010;selective manner within the cerebellar cortex; moreover, biased antagonism effects may allow for further useful therapeutic development.</p><p>This review has focused on cannabinoids as agents acting on the eCB system in the cerebellum; moreover, the modulation of CB<sub>1</sub>Rs has been highlighted. It may transpire that, for exogenous compounds, targeting alternative modes of action offers improved therapeutic potential in diseases such as ataxia. The last few years have seen increasing calls for the use of medical marijuana to treat a range of disorders; of course, use of marijuana is intimately associated with psychoactive effects of the CB<sub>1</sub>R partial agonist &#x00394;<sup>9</sup>&#x02010;THC. Therapeutically, a more attractive option may be use of non&#x02010;psychoactive pCBs. Thus, CBD and cannabidivarin (CBDV) have reported utility in epilepsy and, potentially, other CNS disorders (Hill <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0026" ref-type="ref">2012</xref>
<italic>b</italic>, <xref rid="tjp7198-bib-0028" ref-type="ref">2013</xref>; Devinsky <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0013" ref-type="ref">2014</xref>). The demonstration that Sativex can improve motor activity in multiple sclerosis (Feli&#x000fa; <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0017" ref-type="ref">2015</xref>) is consistent with beneficial effects of a CB<sub>1</sub>R activator (&#x00394;<sup>9</sup>&#x02010;THC) in combination with CBD as a potential ameliorating agent for unwanted &#x00394;<sup>9</sup>&#x02010;THC effects (McPartland <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0052" ref-type="ref">2015</xref>); for example, CBD alone was also effective in improving motor deficits, potentially via an action on peroxisome proliferator&#x02010;activated receptor &#x003b3; (PPAR&#x003b3;) receptors (Feli&#x000fa; <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0017" ref-type="ref">2015</xref>). In this regard, CBD has recently been awarded orphan drug status for the severe childhood epilepsy Dravet syndrome and is currently progressing well through clinical trials. CBD and CBDV have only low affinity at CB<sub>1</sub>Rs and CBD has been proposed, amongst other possibilities, to act at alternative GPCRs or at transient receptor potential ion channels or, possibly, to augment eCB tone via effects on metabolic enzymes (Hill <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0027" ref-type="ref">2012</xref>
<italic>a</italic>; McPartland <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0052" ref-type="ref">2015</xref>). A recent study has proposed that CBD, as well as having CB<sub>1</sub>R&#x02010;independent actions, may also act as a CB<sub>1</sub>R negative allosteric antagonist (Laprairie <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0043" ref-type="ref">2015</xref>); therefore, CBD may share useful properties of this class of agents discussed above. It is also of interest that the hypophagic effects of the allosteric antagonist Org27569 have been suggested to occur independently of CB<sub>1</sub>Rs (Ding <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0014" ref-type="ref">2014</xref>; Gamage <italic>et&#x000a0;al</italic>. <xref rid="tjp7198-bib-0021" ref-type="ref">2014</xref>). Thus, the use of cannabinoids with CB<sub>1</sub>R&#x02010;independent and/or allosteric actions should also be considered.</p><p>In the future, it will be of interest in particular to test agents such as Sativex, and perhaps CBD as an individual compound, in cerebellar ataxia. There are a number of general points to consider, including whether deficits in CB<sub>1</sub>R&#x02010;mediated signalling are hallmark characteristics of different forms of ataxia, how best to target such deficits and whether aberrant cannabinergic signalling represents a useful biomarker for early or asymptomatic cerebellar ataxia. The answer to such questions will go some way to determining if modulation of the eCB system has therapeutic utility in cerebellar ataxia.</p></sec><sec id="tjp7198-sec-0060"><title>Additional information</title><sec id="tjp7198-sec-0070"><title>Competing interests</title><p>The author has no conflict of interest.</p></sec><sec id="tjp7198-sec-0080"><title>Funding</title><p>Work in my group included here was supported by The Wellcome Trust and an Ataxia UK Postgraduate Fellowship awarded to Xiaowei Wang, who also received a University of Reading Postgraduate Research Studentship Award and was co&#x02010;supervised by Prof. Benjamin Whalley. I also acknowledge the support of GW Pharmaceuticals in supplying material and associated grant funding during some of this work.</p></sec></sec></body><back><bio id="d36e56"><p>
<bold>Gary Stephens</bold> held postdoctoral and Fellowship positions with Wyeth Research, Imperial College and University College London before moving to University of Reading in 2005, where he is now Professor of Pharmacology and Director of Pharmacology and Therapeutics. His research interests are in the modulation of presynaptic calcium channels and G protein&#x02010;coupled receptors, with a particular interest in cerebellar function.</p><graphic xlink:href="TJP-594-4631-g001.gif" position="anchor" id="nlm-graphic-1" orientation="portrait"/></bio><ref-list id="tjp7198-bibl-0001"><title>References</title><ref id="tjp7198-bib-0001"><mixed-citation publication-type="journal" id="tjp7198-cit-0001">
<string-name>
<surname>Aiba</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Stanton</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Fox</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Herrup</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Zwingman</surname>
<given-names>TA</given-names>
</string-name> &#x00026; <string-name>
<surname>Tonegawa</surname>
<given-names>S</given-names>
</string-name> (<year>1994</year>). <article-title>Deficient cerebellar long&#x02010;term depression and impaired motor learning in mGluR1 mutant mice</article-title>. <source>Cell</source>
<volume>79</volume>, <fpage>377</fpage>&#x02013;<lpage>388</lpage>.<pub-id pub-id-type="pmid">7954803</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0002"><mixed-citation publication-type="journal" id="tjp7198-cit-0002">
<string-name>
<surname>Arjmand</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Vaziri</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Behzadi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Abbassian</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Stephens</surname>
<given-names>GJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Shabani</surname>
<given-names>M</given-names>
</string-name> (<year>2015</year>). <article-title>Cannabinoids and tremor induced by motor&#x02010;related disorders: friend or foe?</article-title>
<source>Neurotherapeutics</source>
<volume>12</volume>, <fpage>778</fpage>&#x02013;<lpage>787</lpage>.<pub-id pub-id-type="pmid">26152606</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0003"><mixed-citation publication-type="journal" id="tjp7198-cit-0003">
<string-name>
<surname>Baillie</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Horswill</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Anavi&#x02010;Goffer</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Reggio</surname>
<given-names>PH</given-names>
</string-name>, <string-name>
<surname>Bolognini</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Abood</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>McAllister</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Strange</surname>
<given-names>PG</given-names>
</string-name>, <string-name>
<surname>Stephens</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Pertwee</surname>
<given-names>RG</given-names>
</string-name> &#x00026; <string-name>
<surname>Ross</surname>
<given-names>RA</given-names>
</string-name> (<year>2013</year>). <article-title>CB<sub>1</sub> receptor allosteric modulators display both agonist and signaling pathway specificity</article-title>. <source>Mol Pharmacol</source>
<volume>83</volume>, <fpage>322</fpage>&#x02013;<lpage>338</lpage>.<pub-id pub-id-type="pmid">23160940</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0004"><mixed-citation publication-type="journal" id="tjp7198-cit-0004">
<string-name>
<surname>Barclay</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Balaguero</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mione</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ackerman</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Letts</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Brodbeck</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Canti</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Meir</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Page</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Kusumi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Perez&#x02010;Reyes</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Lander</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Frankel</surname>
<given-names>WN</given-names>
</string-name>, <string-name>
<surname>Gardiner</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Dolphin</surname>
<given-names>AC</given-names>
</string-name> &#x00026; <string-name>
<surname>Rees</surname>
<given-names>M</given-names>
</string-name> (<year>2001</year>). <article-title>Ducky mouse phenotype of epilepsy and ataxia is associated with mutations in the Cacna2d2 gene and decreased calcium channel current in cerebellar PCs</article-title>. <source>J Neurosci</source>
<volume>21</volume>, <fpage>6095</fpage>&#x02013;<lpage>6104</lpage>.<pub-id pub-id-type="pmid">11487633</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0005"><mixed-citation publication-type="journal" id="tjp7198-cit-0005">
<string-name>
<surname>Bilkei&#x02010;Gorzo</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Racz</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Valverde</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Otto</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Michel</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Sastre</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Zimmer</surname>
<given-names>A</given-names>
</string-name> (<year>2005</year>). <article-title>Early age&#x02010;related cognitive impairment in mice lacking cannabinoid CB<sub>1</sub> receptors</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>102</volume>, <fpage>15670</fpage>&#x02013;<lpage>15675</lpage>.<pub-id pub-id-type="pmid">16221768</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0006"><mixed-citation publication-type="journal" id="tjp7198-cit-0006">
<string-name>
<surname>Brodbeck</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Courtney</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Meir</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Balaguero</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Canti</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Moss</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Page</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Pratt</surname>
<given-names>WS</given-names>
</string-name>, <string-name>
<surname>Hunt</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Barclay</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Rees</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Dolphin</surname>
<given-names>AC</given-names>
</string-name> (<year>2002</year>). <article-title>The ducky mutation in Cacna2d2 results in altered Purkinje cell morphology and is associated with the expression of a truncated &#x003b1;2&#x003b4;&#x02010;2 protein with abnormal function</article-title>. <source>J Biol Chem</source>
<volume>277</volume>, <fpage>7684</fpage>&#x02013;<lpage>7693</lpage>.<pub-id pub-id-type="pmid">11756448</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0007"><mixed-citation publication-type="journal" id="tjp7198-cit-0007">
<string-name>
<surname>Brown</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Safo</surname>
<given-names>PK</given-names>
</string-name> &#x00026; <string-name>
<surname>Regehr</surname>
<given-names>WG</given-names>
</string-name> (<year>2004</year>). <article-title>Endocannabinoids inhibit transmission at granule cell to Purkinje cell synapses by modulating three types of presynaptic calcium channels</article-title>. <source>J Neurosci</source>
<volume>24</volume>, <fpage>5623</fpage>&#x02013;<lpage>5631</lpage>.<pub-id pub-id-type="pmid">15201335</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0008"><mixed-citation publication-type="journal" id="tjp7198-cit-0008">
<string-name>
<surname>Chen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Abeliovich</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bao</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>RF</given-names>
</string-name> &#x00026; <string-name>
<surname>Tonegawa</surname>
<given-names>S</given-names>
</string-name> (<year>1995</year>). <article-title>Impaired motor coordination correlates with persistent multiple climbing fiber innervation in PKC&#x003b3; mutant mice</article-title>. <source>Cell</source>
<volume>83</volume>, <fpage>1233</fpage>&#x02013;<lpage>1242</lpage>.<pub-id pub-id-type="pmid">8548809</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0009"><mixed-citation publication-type="journal" id="tjp7198-cit-0009">
<string-name>
<surname>Clifford</surname>
<given-names>DB</given-names>
</string-name> (<year>1983</year>). <article-title>Tetrahydrocannabinol for tremor in multiple sclerosis</article-title>. <source>Ann Neurol</source>
<volume>13</volume>, <fpage>669</fpage>&#x02013;<lpage>671</lpage>.<pub-id pub-id-type="pmid">6309074</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0010"><mixed-citation publication-type="journal" id="tjp7198-cit-0010">
<string-name>
<surname>Cole</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Lechner</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Prodanovich</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Bleicher</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Varney</surname>
<given-names>MA</given-names>
</string-name> &#x00026; <string-name>
<surname>Gu</surname>
<given-names>G</given-names>
</string-name> (<year>2005</year>). <article-title>Differential distribution of voltage&#x02010;gated calcium channel alpha&#x02010;2 delta (&#x003b1;2&#x003b4;) subunit mRNA&#x02010;containing cells in the rat central nervous system and the dorsal root ganglia</article-title>. <source>J Comp Neurol</source>
<volume>491</volume>, <fpage>246</fpage>&#x02013;<lpage>269</lpage>.<pub-id pub-id-type="pmid">16134135</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0011"><mixed-citation publication-type="journal" id="tjp7198-cit-0011">
<string-name>
<surname>Cooper</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Korlipara</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Hart</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Bradley</surname>
<given-names>JL</given-names>
</string-name> &#x00026; <string-name>
<surname>Schapira</surname>
<given-names>AH</given-names>
</string-name> (<year>2008</year>). <article-title>Coenzyme Q10 and vitamin E deficiency in Friedreich's ataxia: predictor of efficacy of vitamin E and CoQ10 therapy</article-title>. <source>Eur J Neurol</source>
<volume>15</volume>, <fpage>1371</fpage>&#x02013;<lpage>1379</lpage>.<pub-id pub-id-type="pmid">19049556</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0012"><mixed-citation publication-type="journal" id="tjp7198-cit-0012">
<string-name>
<surname>DeSanty</surname>
<given-names>KP</given-names>
</string-name> &#x00026; <string-name>
<surname>Dar</surname>
<given-names>MS</given-names>
</string-name> (<year>2001</year>). <article-title>Cannabinoid&#x02010;induced motor incoordination through the cerebellar CB<sub>1</sub> receptor in mice</article-title>. <source>Pharmacol Biochem Behav</source>
<volume>69</volume>, <fpage>251</fpage>&#x02013;<lpage>259</lpage>.<pub-id pub-id-type="pmid">11420093</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0013"><mixed-citation publication-type="journal" id="tjp7198-cit-0013">
<string-name>
<surname>Devinsky</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Cilio</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Cross</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Fernandez&#x02010;Ruiz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>French</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hill</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Katz</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Di Marzo</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Jutras&#x02010;Aswad</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Notcutt</surname>
<given-names>WG</given-names>
</string-name>, <string-name>
<surname>Martinez&#x02010;Orgado</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Robson</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Rohrback</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Thiele</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Whalley</surname>
<given-names>B</given-names>
</string-name> &#x00026; <string-name>
<surname>Friedman</surname>
<given-names>D</given-names>
</string-name> (<year>2014</year>). <article-title>Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders</article-title>. <source>Epilepsia</source>
<volume>55</volume>, <fpage>791</fpage>&#x02013;<lpage>802</lpage>.<pub-id pub-id-type="pmid">24854329</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0014"><mixed-citation publication-type="journal" id="tjp7198-cit-0014">
<string-name>
<surname>Ding</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Qiu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jing</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Thorn</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</string-name> &#x00026; <string-name>
<surname>Li</surname>
<given-names>JX</given-names>
</string-name> (<year>2014</year>). <article-title>Behavioral effects of the cannabinoid CB<sub>1</sub> receptor allosteric modulator ORG27569 in rats</article-title>. <source>Pharmacol Res Perspect</source>
<volume>2</volume>, <fpage>e00069</fpage>.<pub-id pub-id-type="pmid">25431655</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0015"><mixed-citation publication-type="journal" id="tjp7198-cit-0015">
<string-name>
<surname>Dolphin</surname>
<given-names>AC</given-names>
</string-name> (<year>2012</year>). <article-title>Calcium channel auxiliary &#x003b1;2&#x003b4; and &#x003b2; subunits: trafficking and one step beyond</article-title>. <source>Nat Rev Neurosci</source>
<volume>13</volume>, <fpage>542</fpage>&#x02013;<lpage>555</lpage>.<pub-id pub-id-type="pmid">22805911</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0016"><mixed-citation publication-type="journal" id="tjp7198-cit-0016">
<string-name>
<surname>Donato</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Page</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Koch</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Nieto&#x02010;Rostro</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Foucault</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Davies</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wilkinson</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Rees</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>FA</given-names>
</string-name> &#x00026; <string-name>
<surname>Dolphin</surname>
<given-names>AC</given-names>
</string-name> (<year>2006</year>). <article-title>The ducky<sup>2J</sup> mutation in Cacna2d2 results in reduced spontaneous Purkinje cell activity and altered gene expression</article-title>. <source>J Neurosci</source>
<volume>26</volume>, <fpage>12576</fpage>&#x02013;<lpage>12586</lpage>.<pub-id pub-id-type="pmid">17135419</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0017"><mixed-citation publication-type="journal" id="tjp7198-cit-0017">
<string-name>
<surname>Feli&#x000fa;</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Moreno&#x02010;Martet</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mecha</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Carrillo&#x02010;Salinas</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>de Lago</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Fern&#x000e1;ndez&#x02010;Ruiz</surname>
<given-names>J</given-names>
</string-name> &#x00026; <string-name>
<surname>Guaza</surname>
<given-names>C</given-names>
</string-name> (<year>2015</year>). <article-title>A Sativex&#x000ae;&#x02010;like combination of phytocannabinoids as a disease&#x02010;modifying therapy in a viral model of multiple sclerosis</article-title>. <source>Br J Pharmacol</source>
<volume>172</volume>, <fpage>3579</fpage>&#x02013;<lpage>3595</lpage>.<pub-id pub-id-type="pmid">25857324</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0018"><mixed-citation publication-type="journal" id="tjp7198-cit-0018">
<string-name>
<surname>Fern&#x000e1;ndez&#x02010;Ruiz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Moreno&#x02010;Martet</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rodr&#x000ed;guez&#x02010;Cueto</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Palomo&#x02010;Garo</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>G&#x000f3;mez&#x02010;Ca&#x000f1;as</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Valdeolivas</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Guaza</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Romero</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Guzm&#x000e1;n</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Mechoulam</surname>
<given-names>R</given-names>
</string-name> &#x00026; <string-name>
<surname>Ramos</surname>
<given-names>JA</given-names>
</string-name> (<year>2011</year>). <article-title>Prospects for cannabinoid therapies in basal ganglia disorders</article-title>. <source>Br J Pharmacol</source>
<volume>163</volume>, <fpage>1365</fpage>&#x02013;<lpage>1378</lpage>.<pub-id pub-id-type="pmid">21545415</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0019"><mixed-citation publication-type="journal" id="tjp7198-cit-0019">
<string-name>
<surname>Forti</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pouzat</surname>
<given-names>C</given-names>
</string-name> &#x00026; <string-name>
<surname>Llano</surname>
<given-names>I</given-names>
</string-name> (<year>2000</year>). <article-title>Action potential&#x02010;evoked Ca<sup>2+</sup> signals and calcium channels in axons of developing rat cerebellar interneurones</article-title>. <source>J Physiol</source>
<volume>527</volume>, <fpage>33</fpage>&#x02013;<lpage>48</lpage>.<pub-id pub-id-type="pmid">10944168</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0020"><mixed-citation publication-type="journal" id="tjp7198-cit-0020">
<string-name>
<surname>Galante</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Diana</surname>
<given-names>MA</given-names>
</string-name> (<year>2004</year>). <article-title>Group I metabotropic glutamate receptors inhibit GABA release at interneuron&#x02010;Purkinje cell synapses through endocannabinoid production</article-title>. <source>J Neurosci</source>
<volume>24</volume>, <fpage>4865</fpage>&#x02013;<lpage>4874</lpage>.<pub-id pub-id-type="pmid">15152047</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0021"><mixed-citation publication-type="journal" id="tjp7198-cit-0021">
<string-name>
<surname>Gamage</surname>
<given-names>TF</given-names>
</string-name>, <string-name>
<surname>Ignatowska&#x02010;Jankowska</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Wiley</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Abdelrahman</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Trembleau</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Greig</surname>
<given-names>IR</given-names>
</string-name>, <string-name>
<surname>Thakur</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Tichkule</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Poklis</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Pertwee</surname>
<given-names>RG</given-names>
</string-name> &#x00026; <string-name>
<surname>Lichtman</surname>
<given-names>AH</given-names>
</string-name> (<year>2014</year>). <article-title>
<italic>In&#x02010;vivo</italic> pharmacological evaluation of the CB<sub>1</sub>&#x02010;receptor allosteric modulator Org&#x02010;27569</article-title>. <source>Behav Pharmacol</source>
<volume>25</volume>, <fpage>182</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">24603340</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0022"><mixed-citation publication-type="journal" id="tjp7198-cit-0022">
<string-name>
<surname>Gao</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Todorov</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Barrett</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>van Dorp</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ferrari</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>van den Maagdenberg</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>De Zeeuw</surname>
<given-names>CI</given-names>
</string-name> &#x00026; <string-name>
<surname>Hoebeek</surname>
<given-names>FE</given-names>
</string-name> (<year>2012</year>). <article-title>Cerebellar ataxia by enhanced Ca<sub>V</sub>2.1 currents is alleviated by Ca<sup>2+</sup>&#x02010;dependent K<sup>+</sup>&#x02010;channel activators in Cacna1a(S218L) mutant mice</article-title>. <source>J Neurosci</source>
<volume>32</volume>, <fpage>15533</fpage>&#x02013;<lpage>15546</lpage>.<pub-id pub-id-type="pmid">23115190</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0023"><mixed-citation publication-type="journal" id="tjp7198-cit-0023">
<string-name>
<surname>Guo</surname>
<given-names>J</given-names>
</string-name> &#x00026; <string-name>
<surname>Ikeda</surname>
<given-names>SR</given-names>
</string-name> (<year>2004</year>). <article-title>Endocannabinoids modulate N&#x02010;type calcium channels and G&#x02010;protein&#x02010;coupled inwardly rectifying potassium channels via CB<sub>1</sub> cannabinoid receptors heterologously expressed in mammalian neurons</article-title>. <source>Mol Pharmacol</source>
<volume>65</volume>, <fpage>665</fpage>&#x02013;<lpage>674</lpage>.<pub-id pub-id-type="pmid">14978245</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0024"><mixed-citation publication-type="journal" id="tjp7198-cit-0024">
<string-name>
<surname>Hampson</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Grimaldi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Axelrod</surname>
<given-names>J</given-names>
</string-name> &#x00026; <string-name>
<surname>Wink</surname>
<given-names>D</given-names>
</string-name> (<year>1998</year>). <article-title>Cannabidiol and (&#x02010;)&#x00394;<sup>9</sup>&#x02010;tetrahydrocannabinol are neuroprotective antioxidants</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>95</volume>, <fpage>8268</fpage>&#x02013;<lpage>8273</lpage>.<pub-id pub-id-type="pmid">9653176</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0025"><mixed-citation publication-type="journal" id="tjp7198-cit-0025">
<string-name>
<surname>Herkenham</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Groen</surname>
<given-names>BG</given-names>
</string-name>, <string-name>
<surname>Lynn</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>De Costa</surname>
<given-names>BR</given-names>
</string-name> &#x00026; <string-name>
<surname>Richfield</surname>
<given-names>EK</given-names>
</string-name> (<year>1991</year>). <article-title>Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum</article-title>. <source>Brain Res</source>
<volume>552</volume>, <fpage>301</fpage>&#x02013;<lpage>310</lpage>.<pub-id pub-id-type="pmid">1913192</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0026"><mixed-citation publication-type="journal" id="tjp7198-cit-0026">
<string-name>
<surname>Hill</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Mercier</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Hill</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Glyn</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Yamasaki</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Futamura</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Duncan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Stott</surname>
<given-names>CG</given-names>
</string-name>, <string-name>
<surname>Stephens</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>CM</given-names>
</string-name> &#x00026; <string-name>
<surname>Whalley</surname>
<given-names>BJ</given-names>
</string-name> (<year>2012</year>
<italic>b</italic>). <article-title>Cannabidivarin is anticonvulsant in mouse and rat in vitro and in seizure models</article-title>. <source>Br J Pharmacol</source>
<volume>167</volume>, <fpage>1629</fpage>&#x02013;<lpage>1642</lpage>.<pub-id pub-id-type="pmid">22970845</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0027"><mixed-citation publication-type="journal" id="tjp7198-cit-0027">
<string-name>
<surname>Hill</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Whalley</surname>
<given-names>BJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Stephens</surname>
<given-names>GJ</given-names>
</string-name> (<year>2012</year>
<italic>a</italic>). <article-title>Phytocannabinoids as novel therapeutic agents in CNS disorders</article-title>. <source>Pharmacol Ther</source>
<volume>133</volume>, <fpage>79</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">21924288</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0028"><mixed-citation publication-type="journal" id="tjp7198-cit-0028">
<string-name>
<surname>Hill</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Cascio</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Romano</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Duncan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pertwee</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Williams</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Whalley</surname>
<given-names>BJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Hill</surname>
<given-names>AJ</given-names>
</string-name> (<year>2013</year>). <article-title>Cannabidivarin&#x02010;rich cannabis extracts are anticonvulsant in mouse and rat via a CB<sub>1</sub> receptor&#x02010;independent mechanism</article-title>. <source>Br J Pharmacol</source>
<volume>170</volume>, <fpage>679</fpage>&#x02013;<lpage>692</lpage>.<pub-id pub-id-type="pmid">23902406</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0029"><mixed-citation publication-type="journal" id="tjp7198-cit-0029">
<string-name>
<surname>Hoppa</surname>
<given-names>MB</given-names>
</string-name>, <string-name>
<surname>Lana</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Margas</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Dolphin</surname>
<given-names>AC</given-names>
</string-name> &#x00026; <string-name>
<surname>Ryan</surname>
<given-names>TA</given-names>
</string-name> (<year>2012</year>). <article-title>&#x003b1;2&#x003b4; expression sets presynaptic calcium channel abundance and release probability</article-title>. <source>Nature</source>
<volume>486</volume>, <fpage>122</fpage>&#x02013;<lpage>125</lpage>.<pub-id pub-id-type="pmid">22678293</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0030"><mixed-citation publication-type="journal" id="tjp7198-cit-0030">
<string-name>
<surname>Horswill</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Bali</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>Shaaban</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Keily</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Jeevaratnam</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Babbs</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Reynet</surname>
<given-names>C</given-names>
</string-name> &#x00026; <string-name>
<surname>Wong Kai In</surname>
<given-names>P</given-names>
</string-name> (<year>2007</year>). <article-title>PSNCBAM&#x02010;1, a novel allosteric antagonist at cannabinoid CB<sub>1</sub> receptors with hypophagic effects in rats</article-title>. <source>Br J Pharmacol</source>
<volume>152</volume>, <fpage>805</fpage>&#x02013;<lpage>814</lpage>.<pub-id pub-id-type="pmid">17592509</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0031"><mixed-citation publication-type="journal" id="tjp7198-cit-0031">
<string-name>
<surname>Howlett</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Blume</surname>
<given-names>LC</given-names>
</string-name> &#x00026; <string-name>
<surname>Dalton</surname>
<given-names>GD</given-names>
</string-name> (<year>2010</year>). <article-title>CB<sub>1</sub> cannabinoid receptors and their associated proteins</article-title>. <source>Curr Med Chem</source>
<volume>17</volume>, <fpage>1382</fpage>&#x02013;<lpage>1393</lpage>.<pub-id pub-id-type="pmid">20166926</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0032"><mixed-citation publication-type="journal" id="tjp7198-cit-0032">
<string-name>
<surname>Ito</surname>
<given-names>M</given-names>
</string-name> (<year>1989</year>). <article-title>Long&#x02010;term depression</article-title>. <source>Annu Rev Neurosci</source>
<volume>12</volume>, <fpage>85</fpage>&#x02013;<lpage>102</lpage>.<pub-id pub-id-type="pmid">2648961</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0033"><mixed-citation publication-type="journal" id="tjp7198-cit-0033">
<string-name>
<surname>Jun</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Piedras&#x02010;Renter&#x000ed;a</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Smith</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Wheeler</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>SB</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Chin</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Adams</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Scheller</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Tsien</surname>
<given-names>RW</given-names>
</string-name> &#x00026; <string-name>
<surname>Shin</surname>
<given-names>HS</given-names>
</string-name> (<year>1999</year>). <article-title>Ablation of P/Q&#x02010;type Ca<sup>2+</sup> channel currents, altered synaptic transmission, and progressive ataxia in mice lacking the &#x003b1;<sub>1A</sub>&#x02010;subunit</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>96</volume>, <fpage>15245</fpage>&#x02013;<lpage>15250</lpage>.<pub-id pub-id-type="pmid">10611370</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0034"><mixed-citation publication-type="journal" id="tjp7198-cit-0034">
<string-name>
<surname>Kaja</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hann</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Payne</surname>
<given-names>HL</given-names>
</string-name> &#x00026; <string-name>
<surname>Thompson</surname>
<given-names>CL</given-names>
</string-name> (<year>2007</year>). <article-title>Aberrant cerebellar granule cell&#x02010;specific GABA<sub>A</sub> receptor expression in the epileptic and ataxic mouse mutant, <italic>Tottering</italic>
</article-title>. <source>Neuroscience</source>
<volume>148</volume>, <fpage>115</fpage>&#x02013;<lpage>125</lpage>.<pub-id pub-id-type="pmid">17614209</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0035"><mixed-citation publication-type="journal" id="tjp7198-cit-0035">
<string-name>
<surname>Kano</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ohno&#x02010;Shosaku</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hashimotodani</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Uchigashima</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Watanabe</surname>
<given-names>M</given-names>
</string-name> (<year>2009</year>). <article-title>Endocannabinoid&#x02010;mediated control of synaptic transmission</article-title>. <source>Physiol Rev</source>
<volume>89</volume>, <fpage>309</fpage>&#x02013;<lpage>380</lpage>.<pub-id pub-id-type="pmid">19126760</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0036"><mixed-citation publication-type="journal" id="tjp7198-cit-0036">
<string-name>
<surname>Kawamura</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fukaya</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Maejima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yoshida</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Miura</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ohno&#x02010;Shosaku</surname>
<given-names>T</given-names>
</string-name> &#x00026; <string-name>
<surname>Kano</surname>
<given-names>M</given-names>
</string-name> (<year>2006</year>). <article-title>CB<sub>1</sub> is the major cannabinoid receptor at excitatory presynaptic site in the hippocampus and cerebellum</article-title>. <source>J Neurosci</source>
<volume>26</volume>, <fpage>2991</fpage>&#x02013;<lpage>3001</lpage>.<pub-id pub-id-type="pmid">16540577</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0037"><mixed-citation publication-type="journal" id="tjp7198-cit-0037">
<string-name>
<surname>Khajehali</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Malone</surname>
<given-names>DT</given-names>
</string-name>, <string-name>
<surname>Glass</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sexton</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Christopoulos</surname>
<given-names>A</given-names>
</string-name> &#x00026; <string-name>
<surname>Leach</surname>
<given-names>K</given-names>
</string-name> (<year>2015</year>). <article-title>Biased agonism and biased allosteric modulation at the CB<sub>1</sub> cannabinoid receptor</article-title>. <source>Mol Pharmacol</source>
<volume>88</volume>, <fpage>368</fpage>&#x02013;<lpage>379</lpage>.<pub-id pub-id-type="pmid">26044547</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0038"><mixed-citation publication-type="journal" id="tjp7198-cit-0038">
<string-name>
<surname>Kishimoto</surname>
<given-names>Y</given-names>
</string-name> &#x00026; <string-name>
<surname>Kano</surname>
<given-names>M</given-names>
</string-name> (<year>2006</year>). <article-title>Endogenous cannabinoid signaling through the CB<sub>1</sub> receptor is essential for cerebellum&#x02010;dependent discrete motor learning</article-title>. <source>J Neurosci</source>
<volume>26</volume>, <fpage>8829</fpage>&#x02013;<lpage>8837</lpage>.<pub-id pub-id-type="pmid">16928872</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0039"><mixed-citation publication-type="journal" id="tjp7198-cit-0039">
<string-name>
<surname>Klockgether</surname>
<given-names>T</given-names>
</string-name> (<year>2011</year>). <article-title>Update on degenerative ataxias</article-title>. <source>Curr Opin Neurol</source>
<volume>24</volume>, <fpage>339</fpage>&#x02013;<lpage>345</lpage>.<pub-id pub-id-type="pmid">21734495</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0040"><mixed-citation publication-type="journal" id="tjp7198-cit-0040">
<string-name>
<surname>Kluger</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Triolo</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Jones</surname>
<given-names>W</given-names>
</string-name> &#x00026; <string-name>
<surname>Jankovic</surname>
<given-names>J</given-names>
</string-name> (<year>2015</year>). <article-title>The therapeutic potential of cannabinoids for movement disorders</article-title>. <source>Mov Disord</source>
<volume>30</volume>, <fpage>313</fpage>&#x02013;<lpage>327</lpage>.<pub-id pub-id-type="pmid">25649017</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0041"><mixed-citation publication-type="journal" id="tjp7198-cit-0041">
<string-name>
<surname>Kreitzer</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Carter</surname>
<given-names>AG</given-names>
</string-name> &#x00026; <string-name>
<surname>Regehr</surname>
<given-names>WG</given-names>
</string-name> (<year>2002</year>). <article-title>Inhibition of interneuron firing extends the spread of endocannabinoid signaling in the cerebellum</article-title>. <source>Neuron</source>
<volume>34</volume>, <fpage>787</fpage>&#x02013;<lpage>796</lpage>.<pub-id pub-id-type="pmid">12062024</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0042"><mixed-citation publication-type="journal" id="tjp7198-cit-0042">
<string-name>
<surname>Kulik</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Nakadate</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Hagiwara</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Fukazawa</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Luj&#x000e1;n</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Saito</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Suzuki</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Futatsugi</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Mikoshiba</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Frotscher</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Shigemoto</surname>
<given-names>R</given-names>
</string-name> (<year>2004</year>). <article-title>Immunocytochemical localization of the &#x003b1;1<sub>A</sub> subunit of the P/Q&#x02010;type calcium channel in the rat cerebellum</article-title>. <source>Eur J Neurosci</source>
<volume>19</volume>, <fpage>2169</fpage>&#x02013;<lpage>2178</lpage>.<pub-id pub-id-type="pmid">15090043</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0043"><mixed-citation publication-type="journal" id="tjp7198-cit-0043">
<string-name>
<surname>Laprairie</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Bagher</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>ME</given-names>
</string-name> &#x00026; <string-name>
<surname>Denovan&#x02010;Wright</surname>
<given-names>EM</given-names>
</string-name> (<year>2015</year>). <article-title>Cannabidiol is a negative allosteric modulator of the type 1 cannabinoid receptor</article-title>. <source>Br J Pharmacol</source>
<volume>172</volume>, <fpage>4790</fpage>&#x02013;<lpage>4805</lpage>.<pub-id pub-id-type="pmid">26218440</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0044"><mixed-citation publication-type="journal" id="tjp7198-cit-0044">
<string-name>
<surname>Laprairie</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Bagher</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Kelly</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Dupr&#x000e9;</surname>
<given-names>DJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Denovan&#x02010;Wright</surname>
<given-names>EM</given-names>
</string-name> (<year>2014</year>). <article-title>Type 1 cannabinoid receptor ligands display functional selectivity in a cell culture model of striatal medium spiny projection neurons</article-title>. <source>J Biol Chem</source>
<volume>289</volume>, <fpage>24845</fpage>&#x02013;<lpage>24862</lpage>.<pub-id pub-id-type="pmid">25037227</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0045"><mixed-citation publication-type="journal" id="tjp7198-cit-0045">
<string-name>
<surname>Lichtman</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Wiley</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>LaVecchia</surname>
<given-names>KL</given-names>
</string-name>, <string-name>
<surname>Neviaser</surname>
<given-names>ST</given-names>
</string-name>, <string-name>
<surname>Arthur</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>DM</given-names>
</string-name> &#x00026; <string-name>
<surname>Martin</surname>
<given-names>BR</given-names>
</string-name> (<year>1998</year>). <article-title>Effects of SR 141716A after acute or chronic cannabinoid administration in dogs</article-title>. <source>Eur J Pharmacol</source>
<volume>357</volume>, <fpage>139</fpage>&#x02013;<lpage>148</lpage>.<pub-id pub-id-type="pmid">9797029</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0046"><mixed-citation publication-type="journal" id="tjp7198-cit-0046">
<string-name>
<surname>Lonchamp</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Dupont</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Doussau</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Poulain</surname>
<given-names>B</given-names>
</string-name> &#x00026; <string-name>
<surname>Bossu</surname>
<given-names>JL</given-names>
</string-name> (<year>2009</year>). <article-title>Deletion of Ca<sub>V</sub>2.1(&#x003b1;1A) subunit of Ca<sup>2+</sup>&#x02010;channels impairs synaptic GABA and glutamate release in the mouse cerebellar cortex in cultured slices</article-title>. <source>Eur J Neurosci</source>
<volume>30</volume>, <fpage>2293</fpage>&#x02013;<lpage>2307</lpage>.<pub-id pub-id-type="pmid">20092572</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0047"><mixed-citation publication-type="journal" id="tjp7198-cit-0047">
<string-name>
<surname>Lynch</surname>
<given-names>DR</given-names>
</string-name>, <string-name>
<surname>Perlman</surname>
<given-names>SL</given-names>
</string-name> &#x00026; <string-name>
<surname>Meier</surname>
<given-names>T</given-names>
</string-name> (<year>2010</year>). <article-title>A phase 3, double&#x02010;blind, placebo&#x02010;controlled trial of idebenone in Friedreich ataxia</article-title>. <source>Arch Neurol</source>
<volume>67</volume>, <fpage>941</fpage>&#x02013;<lpage>947</lpage>.<pub-id pub-id-type="pmid">20697044</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0048"><mixed-citation publication-type="journal" id="tjp7198-cit-0048">
<string-name>
<surname>Ma</surname>
<given-names>YL</given-names>
</string-name>, <string-name>
<surname>Weston</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Whalley</surname>
<given-names>BJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Stephens</surname>
<given-names>GJ</given-names>
</string-name> (<year>2008</year>). <article-title>The phytocannabinoid &#x00394;<sup>9</sup>&#x02010;tetrahydrocannabivarin modulates inhibitory neurotransmission in the cerebellum</article-title>. <source>Br J Pharmacol</source>
<volume>154</volume>, <fpage>204</fpage>&#x02013;<lpage>215</lpage>.<pub-id pub-id-type="pmid">18311186</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0049"><mixed-citation publication-type="journal" id="tjp7198-cit-0049">
<string-name>
<surname>Mackie</surname>
<given-names>K</given-names>
</string-name> &#x00026; <string-name>
<surname>Hille</surname>
<given-names>B</given-names>
</string-name> (<year>1992</year>). <article-title>Cannabinoids inhibit N&#x02010;type calcium channels in neuroblastoma&#x02010;glioma cells</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>89</volume>, <fpage>3825</fpage>&#x02013;<lpage>3829</lpage>.<pub-id pub-id-type="pmid">1315042</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0050"><mixed-citation publication-type="journal" id="tjp7198-cit-0050">
<string-name>
<surname>Maejima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Wollenweber</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Teusner</surname>
<given-names>LU</given-names>
</string-name>, <string-name>
<surname>Noebels</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Herlitze</surname>
<given-names>S</given-names>
</string-name> &#x00026; <string-name>
<surname>Mark</surname>
<given-names>MD</given-names>
</string-name> (<year>2013</year>). <article-title>Postnatal loss of P/Q&#x02010;type channels confined to rhombic&#x02010;lip&#x02010;derived neurons alters synaptic transmission at the parallel fiber to purkinje cell synapse and replicates genomic Cacna1a mutation phenotype of ataxia and seizures in mice</article-title>. <source>J Neurosci</source>
<volume>33</volume>, <fpage>5162</fpage>&#x02013;<lpage>5174</lpage>.<pub-id pub-id-type="pmid">23516282</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0051"><mixed-citation publication-type="journal" id="tjp7198-cit-0051">
<string-name>
<surname>Mark</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Maejima</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Kuckelsberg</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Yoo</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Hyde</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Shah</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Gutierrez</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Moreno</surname>
<given-names>RL</given-names>
</string-name>, <string-name>
<surname>Kruse</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Noebels</surname>
<given-names>JL</given-names>
</string-name> &#x00026; <string-name>
<surname>Herlitze</surname>
<given-names>S</given-names>
</string-name> (<year>2011</year>). <article-title>Delayed postnatal loss of P/Q&#x02010;type calcium channels recapitulates the absence epilepsy, dyskinesia, and ataxia phenotypes of genomic Cacna1A mutations</article-title>. <source>J Neurosci</source>
<volume>31</volume>, <fpage>4311</fpage>&#x02013;<lpage>4326</lpage>.<pub-id pub-id-type="pmid">21411672</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0052"><mixed-citation publication-type="journal" id="tjp7198-cit-0052">
<string-name>
<surname>McPartland</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Duncan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Di Marzo</surname>
<given-names>V</given-names>
</string-name> &#x00026; <string-name>
<surname>Pertwee</surname>
<given-names>R</given-names>
</string-name> (<year>2015</year>). <article-title>Are cannabidiol and &#x00394;<sup>9</sup>&#x02010;tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review</article-title>. <source>Br J Pharmacol</source>
<volume>172</volume>, <fpage>737</fpage>&#x02013;<lpage>753</lpage>.<pub-id pub-id-type="pmid">25257544</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0053"><mixed-citation publication-type="journal" id="tjp7198-cit-0053">
<string-name>
<surname>Meinck</surname>
<given-names>HM</given-names>
</string-name>, <string-name>
<surname>Sch&#x000f6;nle</surname>
<given-names>PW</given-names>
</string-name> &#x00026; <string-name>
<surname>Conrad</surname>
<given-names>B</given-names>
</string-name> (<year>1989</year>). <article-title>Effect of cannabinoids on spasticity and ataxia in multiple sclerosis</article-title>. <source>J Neurol</source>
<volume>236</volume>, <fpage>120</fpage>&#x02013;<lpage>122</lpage>.<pub-id pub-id-type="pmid">2709054</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0054"><mixed-citation publication-type="journal" id="tjp7198-cit-0054">
<string-name>
<surname>Mills</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Yap</surname>
<given-names>L</given-names>
</string-name> &#x00026; <string-name>
<surname>Young</surname>
<given-names>CA</given-names>
</string-name> (<year>2007</year>). <article-title>Treatment for ataxia in multiple sclerosis</article-title>. <source>Cochrane Database Syst Rev</source>
<volume>1</volume>, <fpage>CD005029</fpage>.<pub-id pub-id-type="pmid">17253537</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0055"><mixed-citation publication-type="journal" id="tjp7198-cit-0055">
<string-name>
<surname>Mintz</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Sabatini</surname>
<given-names>BL</given-names>
</string-name> &#x00026; <string-name>
<surname>Regehr</surname>
<given-names>WG</given-names>
</string-name> (<year>1995</year>). <article-title>Calcium control of transmitter release at a cerebellar synapse</article-title>. <source>Neuron</source>
<volume>15</volume>, <fpage>675</fpage>&#x02013;<lpage>688</lpage>.<pub-id pub-id-type="pmid">7546746</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0056"><mixed-citation publication-type="journal" id="tjp7198-cit-0056">
<string-name>
<surname>Mintz</surname>
<given-names>IM</given-names>
</string-name>, <string-name>
<surname>Venema</surname>
<given-names>VJ</given-names>
</string-name>, <string-name>
<surname>Swiderek</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>TD</given-names>
</string-name>, <string-name>
<surname>Bean</surname>
<given-names>BP</given-names>
</string-name> &#x00026; <string-name>
<surname>Adams</surname>
<given-names>ME</given-names>
</string-name> (<year>1992</year>). <article-title>P&#x02010;type calcium channels blocked by the spider toxin omega&#x02010;Aga&#x02010;IVA</article-title>. <source>Nature</source>
<volume>355</volume>, <fpage>827</fpage>&#x02013;<lpage>829</lpage>.<pub-id pub-id-type="pmid">1311418</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0057"><mixed-citation publication-type="journal" id="tjp7198-cit-0057">
<string-name>
<surname>Nathan</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>O'Neill</surname>
<given-names>BV</given-names>
</string-name>, <string-name>
<surname>Napolitano</surname>
<given-names>A</given-names>
</string-name> &#x00026; <string-name>
<surname>Bullmore</surname>
<given-names>ET</given-names>
</string-name> (<year>2011</year>). <article-title>Neuropsychiatric adverse effects of centrally acting antiobesity drugs</article-title>. <source>CNS Neurosci Ther</source>
<volume>17</volume>, <fpage>490</fpage>&#x02013;<lpage>505</lpage>.<pub-id pub-id-type="pmid">21951371</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0058"><mixed-citation publication-type="journal" id="tjp7198-cit-0058">
<string-name>
<surname>Ohno&#x02010;Shosaku</surname>
<given-names>T</given-names>
</string-name> &#x00026; <string-name>
<surname>Kano</surname>
<given-names>M</given-names>
</string-name> (<year>2014</year>). <article-title>Endocannabinoid&#x02010;mediated retrograde modulation of synaptic transmission</article-title>. <source>Curr Opin Neurobiol</source>
<volume>29</volume>, <fpage>1</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">24747340</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0059"><mixed-citation publication-type="journal" id="tjp7198-cit-0059">
<string-name>
<surname>Patel</surname>
<given-names>S</given-names>
</string-name> &#x00026; <string-name>
<surname>Hillard</surname>
<given-names>CJ</given-names>
</string-name> (<year>2001</year>). <article-title>Cannabinoid CB<sub>1</sub> receptor agonists produce cerebellar dysfunction in mice</article-title>. <source>J Pharmacol Exp Ther</source>
<volume>297</volume>, <fpage>629</fpage>&#x02013;<lpage>637</lpage>.<pub-id pub-id-type="pmid">11303052</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0060"><mixed-citation publication-type="journal" id="tjp7198-cit-0060">
<string-name>
<surname>Pertwee</surname>
<given-names>RG</given-names>
</string-name>, <string-name>
<surname>Howlett</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Abood</surname>
<given-names>ME</given-names>
</string-name>, <string-name>
<surname>Alexander</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Di Marzo</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Elphick</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Greasley</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Hansen</surname>
<given-names>HS</given-names>
</string-name>, <string-name>
<surname>Kunos</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Mackie</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Mechoulam</surname>
<given-names>R</given-names>
</string-name> &#x00026; <string-name>
<surname>Ross</surname>
<given-names>RA</given-names>
</string-name> (<year>2010</year>). <article-title>International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB&#x02081; and CB&#x02082;</article-title>. <source>Pharmacol Rev</source>
<volume>62</volume>, <fpage>588</fpage>&#x02013;<lpage>631</lpage>.<pub-id pub-id-type="pmid">21079038</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0061"><mixed-citation publication-type="journal" id="tjp7198-cit-0061">
<string-name>
<surname>Pietrobon</surname>
<given-names>D</given-names>
</string-name> (<year>2010</year>). <article-title>Ca<sub>V</sub>2.1 channelopathies</article-title>. <source>Pflugers Arch</source>
<volume>460</volume>, <fpage>375</fpage>&#x02013;<lpage>393</lpage>.<pub-id pub-id-type="pmid">20204399</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0062"><mixed-citation publication-type="journal" id="tjp7198-cit-0062">
<string-name>
<surname>Price</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Baillie</surname>
<given-names>GL</given-names>
</string-name>, <string-name>
<surname>Thomas</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Stevenson</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Easson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>McLean</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>McIntosh</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Goodwin</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Walker</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Westwood</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Marrs</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Thomson</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Cowley</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Christopoulos</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Pertwee</surname>
<given-names>RG</given-names>
</string-name> &#x00026; <string-name>
<surname>Ross</surname>
<given-names>RA</given-names>
</string-name> (<year>2005</year>). <article-title>Allosteric modulation of the cannabinoid CB<sub>1</sub> receptor</article-title>. <source>Mol Pharmacol</source>
<volume>68</volume>, <fpage>1484</fpage>&#x02013;<lpage>1495</lpage>.<pub-id pub-id-type="pmid">16113085</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0063"><mixed-citation publication-type="journal" id="tjp7198-cit-0063">
<string-name>
<surname>Rajakulendran</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kaski</surname>
<given-names>D</given-names>
</string-name> &#x00026; <string-name>
<surname>Hanna</surname>
<given-names>MG</given-names>
</string-name> (<year>2012</year>). <article-title>Neuronal P/Q&#x02010;type calcium channel dysfunction in inherited disorders of the CNS</article-title>. <source>Nat Rev Neurol</source>
<volume>8</volume>, <fpage>86</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">22249839</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0064"><mixed-citation publication-type="journal" id="tjp7198-cit-0064">
<string-name>
<surname>Rodr&#x000ed;guez&#x02010;Cueto</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Benito</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fern&#x000e1;ndez&#x02010;Ruiz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Romero</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hern&#x000e1;ndez&#x02010;G&#x000e1;lvez</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>G&#x000f3;mez&#x02010;Ruiz</surname>
<given-names>M</given-names>
</string-name> (<year>2014</year>
<italic>a</italic>). <article-title>Changes in CB<sub>1</sub> and CB<sub>2</sub> receptors in the post&#x02010;mortem cerebellum of humans affected by spinocerebellar ataxias</article-title>. <source>Br J Pharmacol</source>
<volume>171</volume>, <fpage>1472</fpage>&#x02013;<lpage>1489</lpage>.<pub-id pub-id-type="pmid">23808969</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0065"><mixed-citation publication-type="journal" id="tjp7198-cit-0065">
<string-name>
<surname>Rodr&#x000ed;guez&#x02010;Cueto</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Benito</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Romero</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hern&#x000e1;ndez&#x02010;G&#x000e1;lvez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>G&#x000f3;mez&#x02010;Ruiz</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Fern&#x000e1;ndez&#x02010;Ruiz</surname>
<given-names>J</given-names>
</string-name> (<year>2014</year>
<italic>b</italic>). <article-title>Endocannabinoid&#x02010;hydrolysing enzymes in the post&#x02010;mortem cerebellum of humans affected by hereditary autosomal dominant ataxias</article-title>. <source>Pathobiology</source>
<volume>81</volume>, <fpage>149</fpage>&#x02013;<lpage>159</lpage>.<pub-id pub-id-type="pmid">24642775</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0066"><mixed-citation publication-type="journal" id="tjp7198-cit-0066">
<string-name>
<surname>Regehr</surname>
<given-names>WG</given-names>
</string-name> &#x00026; <string-name>
<surname>Mintz</surname>
<given-names>IM</given-names>
</string-name> (<year>1994</year>). <article-title>Participation of multiple calcium channel types in transmission at single climbing fiber to Purkinje cell synapses</article-title>. <source>Neuron</source>
<volume>12</volume>, <fpage>605</fpage>&#x02013;<lpage>613</lpage>.<pub-id pub-id-type="pmid">8155322</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0067"><mixed-citation publication-type="journal" id="tjp7198-cit-0067">
<string-name>
<surname>Safo</surname>
<given-names>PK</given-names>
</string-name> &#x00026; <string-name>
<surname>Regehr</surname>
<given-names>WG</given-names>
</string-name> (<year>2005</year>). <article-title>Endocannabinoids control the induction of cerebellar LTD</article-title>. <source>Neuron</source>
<volume>48</volume>, <fpage>647</fpage>&#x02013;<lpage>659</lpage>.<pub-id pub-id-type="pmid">16301180</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0068"><mixed-citation publication-type="journal" id="tjp7198-cit-0068">
<string-name>
<surname>Shibusawa</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</string-name> &#x00026; <string-name>
<surname>Yamada</surname>
<given-names>M</given-names>
</string-name> (<year>2008</year>). <article-title>Thyrotropin&#x02010;releasing hormone (TRH) in the cerebellum</article-title>. <source>Cerebellum</source>
<volume>7</volume>, <fpage>84</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">18418668</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0069"><mixed-citation publication-type="journal" id="tjp7198-cit-0069">
<string-name>
<surname>Skosnik</surname>
<given-names>PD</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>O'Donnell</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>O'Donnell</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>Steffen</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Steinmetz</surname>
<given-names>JE</given-names>
</string-name> &#x00026; <string-name>
<surname>Hetrick</surname>
<given-names>WP</given-names>
</string-name> (<year>2008</year>). <article-title>Cannabis use disrupts eyeblink conditioning: evidence for cannabinoid modulation of cerebellar&#x02010;dependent learning</article-title>. <source>Neuropsychopharmacol</source>
<volume>33</volume>, <fpage>1432</fpage>&#x02013;<lpage>1440</lpage>.</mixed-citation></ref><ref id="tjp7198-bib-0070"><mixed-citation publication-type="journal" id="tjp7198-cit-0070">
<string-name>
<surname>Steiner</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Bonner</surname>
<given-names>TI</given-names>
</string-name>, <string-name>
<surname>Zimmer</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Kitai</surname>
<given-names>S</given-names>
</string-name> &#x00026; <string-name>
<surname>Zimmer</surname>
<given-names>A</given-names>
</string-name> (<year>1999</year>). <article-title>Altered gene expression in striatal projection neurons in CB<sub>1</sub> cannabinoid receptor knockout mice</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>96</volume>, <fpage>5786</fpage>&#x02013;<lpage>5790</lpage>.<pub-id pub-id-type="pmid">10318962</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0071"><mixed-citation publication-type="journal" id="tjp7198-cit-0071">
<string-name>
<surname>Steinmetz</surname>
<given-names>AB</given-names>
</string-name> &#x00026; <string-name>
<surname>Freeman</surname>
<given-names>JH</given-names>
</string-name> (<year>2010</year>). <article-title>Central cannabinoid receptors modulate acquisition of eyeblink conditioning</article-title>. <source>Learn Mem</source>
<volume>17</volume>, <fpage>571</fpage>&#x02013;<lpage>576</lpage>.<pub-id pub-id-type="pmid">21030483</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0072"><mixed-citation publication-type="journal" id="tjp7198-cit-0072">
<string-name>
<surname>Stephens</surname>
<given-names>GJ</given-names>
</string-name> (<year>2009</year>). <article-title>G&#x02010;protein&#x02010;coupled&#x02010;receptor&#x02010;mediated presynaptic inhibition in the cerebellum</article-title>. <source>Trends Pharmacol Sci</source>
<volume>30</volume>, <fpage>421</fpage>&#x02013;<lpage>430</lpage>.<pub-id pub-id-type="pmid">19632729</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0073"><mixed-citation publication-type="journal" id="tjp7198-cit-0073">
<string-name>
<surname>Stephens</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Morris</surname>
<given-names>NP</given-names>
</string-name>, <string-name>
<surname>Fyffe</surname>
<given-names>RE</given-names>
</string-name> &#x00026; <string-name>
<surname>Robertson</surname>
<given-names>B</given-names>
</string-name> (<year>2001</year>). <article-title>The Ca<sub>V</sub>2.1/&#x003b1;1A (P/Q&#x02010;type) voltage&#x02010;dependent calcium channel mediates inhibitory neurotransmission onto mouse cerebellar Purkinje cells</article-title>. <source>Eur J Neurosci</source>
<volume>13</volume>, <fpage>1902</fpage>&#x02013;<lpage>1912</lpage>.<pub-id pub-id-type="pmid">11403683</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0074"><mixed-citation publication-type="journal" id="tjp7198-cit-0074">
<string-name>
<surname>Szabo</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Than</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Thorn</surname>
<given-names>D</given-names>
</string-name> &#x00026; <string-name>
<surname>Wallmichrath</surname>
<given-names>I</given-names>
</string-name> (<year>2004</year>). <article-title>Analysis of the effects of cannabinoids on synaptic transmission between basket and Purkinje cells in the cerebellar cortex of the rat</article-title>. <source>J Pharmacol Exp Ther</source>
<volume>310</volume>, <fpage>915</fpage>&#x02013;<lpage>925</lpage>.<pub-id pub-id-type="pmid">15123767</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0075"><mixed-citation publication-type="journal" id="tjp7198-cit-0075">
<string-name>
<surname>Szabo</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Urbanski</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Bisogno</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Di Marzo</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Mendiguren</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Baer</surname>
<given-names>WU</given-names>
</string-name> &#x00026; <string-name>
<surname>Freiman</surname>
<given-names>I</given-names>
</string-name> (<year>2006</year>). <article-title>Depolarization&#x02010;induced retrograde synaptic inhibition in the mouse cerebellar cortex is mediated by 2&#x02010;arachidonoylglycerol</article-title>. <source>J Physiol</source>
<volume>577</volume>, <fpage>263</fpage>&#x02013;<lpage>280</lpage>.<pub-id pub-id-type="pmid">16973696</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0076"><mixed-citation publication-type="journal" id="tjp7198-cit-0076">
<string-name>
<surname>Takahashi</surname>
<given-names>KA</given-names>
</string-name> &#x00026; <string-name>
<surname>Linden</surname>
<given-names>DJ</given-names>
</string-name> (<year>2000</year>). <article-title>Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells</article-title>. <source>J Neurophysiol</source>
<volume>83</volume>, <fpage>1167</fpage>&#x02013;<lpage>1180</lpage>.<pub-id pub-id-type="pmid">10712447</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0077"><mixed-citation publication-type="journal" id="tjp7198-cit-0077">
<string-name>
<surname>Tanimura</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Kawata</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</string-name> &#x00026; <string-name>
<surname>Kano</surname>
<given-names>M</given-names>
</string-name> (<year>2009</year>). <article-title>Not glutamate but endocannabinoids mediate retrograde suppression of cerebellar parallel fiber to Purkinje cell synaptic transmission in young adult rodents</article-title>. <source>Neuropharmacol</source>
<volume>57</volume>, <fpage>157</fpage>&#x02013;<lpage>163</lpage>.</mixed-citation></ref><ref id="tjp7198-bib-0078"><mixed-citation publication-type="journal" id="tjp7198-cit-0078">
<string-name>
<surname>Tanimura</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Uchigashima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yamazaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Uesaka</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Mikuni</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Abe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Watanabe</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sakimura</surname>
<given-names>K</given-names>
</string-name> &#x00026; <string-name>
<surname>Kano</surname>
<given-names>M</given-names>
</string-name> (<year>2012</year>). <article-title>Synapse type&#x02010;independent degradation of the endocannabinoid 2&#x02010;arachidonoylglycerol after retrograde synaptic suppression</article-title>. <source>Proc Natl Acad Sci USA</source>
<volume>109</volume>, <fpage>12195</fpage>&#x02013;<lpage>12200</lpage>.<pub-id pub-id-type="pmid">22783023</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0079"><mixed-citation publication-type="journal" id="tjp7198-cit-0079">
<string-name>
<surname>Todorov</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Kros</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Shyti</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Plak</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Haasdijk</surname>
<given-names>ED</given-names>
</string-name>, <string-name>
<surname>Raike</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Frants</surname>
<given-names>RR</given-names>
</string-name>, <string-name>
<surname>Hess</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Hoebeek</surname>
<given-names>FE</given-names>
</string-name>, <string-name>
<surname>De Zeeuw</surname>
<given-names>CI</given-names>
</string-name> &#x00026; <string-name>
<surname>van den Maagdenberg</surname>
<given-names>AM</given-names>
</string-name> (<year>2012</year>). <article-title>Purkinje cell&#x02010;specific ablation of Ca<sub>V</sub>2.1 channels is sufficient to cause cerebellar ataxia in mice</article-title>. <source>Cerebellum</source>
<volume>11</volume>, <fpage>246</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">21870131</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0080"><mixed-citation publication-type="journal" id="tjp7198-cit-0080">
<string-name>
<surname>Tsou</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Sa&#x000f1;udo&#x02010;Pe&#x000f1;a</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Mackie</surname>
<given-names>K</given-names>
</string-name> &#x00026; <string-name>
<surname>Walker</surname>
<given-names>JM</given-names>
</string-name> (<year>1997</year>). <article-title>Immunohistochemical distribution of cannabinoid CB<sub>1</sub> receptors in the rat central nervous system</article-title>. <source>Neuroscience</source>
<volume>83</volume>, <fpage>393</fpage>&#x02013;<lpage>411</lpage>.<pub-id pub-id-type="pmid">9460749</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0081"><mixed-citation publication-type="journal" id="tjp7198-cit-0081">
<string-name>
<surname>Twitchell</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>S</given-names>
</string-name> &#x00026; <string-name>
<surname>Mackie</surname>
<given-names>K</given-names>
</string-name> (<year>1997</year>). <article-title>Cannabinoids inhibit N&#x02010; and P/Q&#x02010;type calcium channels in cultured rat hippocampal neurons</article-title>
<source>J Neurophysiol</source>
<volume>78</volume>, <fpage>43</fpage>&#x02013;<lpage>50</lpage>.<pub-id pub-id-type="pmid">9242259</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0082"><mixed-citation publication-type="journal" id="tjp7198-cit-0082">
<string-name>
<surname>Walter</surname>
<given-names>JT</given-names>
</string-name>, <string-name>
<surname>Alvi&#x000f1;a</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Womack</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Chevez</surname>
<given-names>C</given-names>
</string-name> &#x00026; <string-name>
<surname>Khodakhah</surname>
<given-names>K</given-names>
</string-name> (<year>2006</year>). <article-title>Decreases in the precision of Purkinje cell pacemaking cause cerebellar dysfunction and ataxia</article-title>. <source>Nat Neurosci</source>
<volume>9</volume>, <fpage>389</fpage>&#x02013;<lpage>397</lpage>.<pub-id pub-id-type="pmid">16474392</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0083"><mixed-citation publication-type="journal" id="tjp7198-cit-0083">
<string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Horswill</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Whalley</surname>
<given-names>BJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Stephens</surname>
<given-names>GJ</given-names>
</string-name> (<year>2011</year>). <article-title>Effects of the allosteric antagonist PSNCBAM&#x02010;1 on CB<sub>1</sub> receptor modulation in the cerebellum</article-title>. <source>Mol Pharmacol</source>
<volume>79</volume>, <fpage>758</fpage>&#x02013;<lpage>767</lpage>.<pub-id pub-id-type="pmid">21189269</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0084"><mixed-citation publication-type="journal" id="tjp7198-cit-0084">
<string-name>
<surname>Wang</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Whalley</surname>
<given-names>BJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Stephens</surname>
<given-names>GJ</given-names>
</string-name> (<year>2013</year>). <article-title>The <italic>du<sup>2J</sup></italic> mouse model of ataxia and absence epilepsy has deficient cannabinoid CB<sub>1</sub> receptor&#x02010;mediated signalling</article-title>. <source>J Physiol</source>
<volume>591</volume>, <fpage>3919</fpage>&#x02013;<lpage>3933</lpage>.<pub-id pub-id-type="pmid">23732642</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0085"><mixed-citation publication-type="journal" id="tjp7198-cit-0085">
<string-name>
<surname>Westenbroek</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Sakurai</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Elliott</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Hell</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Starr</surname>
<given-names>TV</given-names>
</string-name>, <string-name>
<surname>Snutch</surname>
<given-names>TP</given-names>
</string-name> &#x00026; <string-name>
<surname>Catterall</surname>
<given-names>WA</given-names>
</string-name> (<year>1995</year>). <article-title>Immunochemical identification and subcellular distribution of the alpha 1A subunits of brain calcium channels</article-title>. <source>J Neurosci</source>
<volume>15</volume>, <fpage>6403</fpage>&#x02013;<lpage>6418</lpage>.<pub-id pub-id-type="pmid">7472404</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0086"><mixed-citation publication-type="journal" id="tjp7198-cit-0086">
<string-name>
<surname>Yamasaki</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Hashimoto</surname>
<given-names>K</given-names>
</string-name> &#x00026; <string-name>
<surname>Kano</surname>
<given-names>M</given-names>
</string-name> (<year>2006</year>). <article-title>Miniature synaptic events elicited by presynaptic Ca<sup>2+</sup> rise are selectively suppressed by cannabinoid receptor activation in cerebellar Purkinje cells</article-title>. <source>J Neurosci</source>
<volume>26</volume>, <fpage>86</fpage>&#x02013;<lpage>95</lpage>.<pub-id pub-id-type="pmid">16399675</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0087"><mixed-citation publication-type="journal" id="tjp7198-cit-0087">
<string-name>
<surname>Yoshida</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Fukaya</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Uchigashima</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Miura</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Kamiya</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kano</surname>
<given-names>M</given-names>
</string-name> &#x00026; <string-name>
<surname>Watanabe</surname>
<given-names>M</given-names>
</string-name> (<year>2006</year>). <article-title>Localization of diacylglycerol lipase&#x02010;alpha around postsynaptic spine suggests close proximity between production site of an endocannabinoid, 2&#x02010;arachidonoyl&#x02010;glycerol, and presynaptic cannabinoid CB<sub>1</sub> receptor</article-title>. <source>J Neurosci</source>
<volume>26</volume>, <fpage>4740</fpage>&#x02013;<lpage>4751</lpage>.<pub-id pub-id-type="pmid">16672646</pub-id></mixed-citation></ref><ref id="tjp7198-bib-0088"><mixed-citation publication-type="journal" id="tjp7198-cit-0088">
<string-name>
<surname>Zhou</surname>
<given-names>YD</given-names>
</string-name>, <string-name>
<surname>Turner</surname>
<given-names>TJ</given-names>
</string-name> &#x00026; <string-name>
<surname>Dunlap</surname>
<given-names>K</given-names>
</string-name> (<year>2003</year>). <article-title>Enhanced G protein&#x02010;dependent modulation of excitatory synaptic transmission in the cerebellum of the Ca<sup>2+</sup> channel&#x02010;mutant mouse, <italic>tottering</italic>
</article-title>. <source>J Physiol</source>
<volume>547</volume>, <fpage>497</fpage>&#x02013;<lpage>507</lpage>.<pub-id pub-id-type="pmid">12562906</pub-id></mixed-citation></ref></ref-list></back></article>